1304

INDEX

Volume 276, January-March, 1996

A-77636, studies, receptor desensitization,

dopamine D1 receptor effects,1022

A-127722, pharmacological characteriza-tion, 473

An, E. M. van der, Wouterse, A. C., Verrijt,C. E. H., Peereboom-Stegeman, J.H. J. C. and Russel, F. G. M.: Up-take of cimetidine into syncytialmicrovillus membrane vesicles of

human term placenta, 219Abboa-Offei, B. E., see Seymour, A. A., 708

Abbruscato, T. J., Williams, S. A., Isicka,A. M., Lipkowski, A. W., Hruby,V. J. and Davis, T. P.: Blood-to-central nervous system entry andstability of (Try-D-Ala-Gly-Phe-NH)2 a unique double-enkepha-lin analog, and its halogenatedderivatives, 1049

Abe, Y., Ishisu, R., Onishi, K., Sekioka, K.,

Narimatsu, A. and Nakano, T.:Calcium sensitization in perfusedbeating guinea pig heart by a pos-itive inotropic agent MCI-154,433

Abi-Younes, S., see Farhat, M. Y., 652ABT-431, in vitro characterization and ef-

fects in animal models of Parkin-

son’s disease, 150

Acetylcholinechloride current oscillations, in swine

tracheal smooth muscle cells, 178release, gastric motility and, TKS159 ef-

fects, guinea pig stomach, 989Acetylcholine receptors

nicotinica4�2, expression, pharmacologic prop-

erties and regulation, 289agonist epibatidine, effects on neuro-

transmitter release, in rats, 509neural effects in medial septum, 482reduction by nereistoxin, whole chick

ciliary ganglion studies, 169

presynaptic control of dopamine release

by, in rat striatum synaptosomes,616

Acidification, urine, enhancement of or-ganic cation secretion by, 683

Acrylamide neuropathy, 4-methylcatechol

effects on recovery from, 231

Adenosine receptorsA1, antagonist WRC-0571, characteriza-

tion, 490A2a antagonist SCH 58261, pharmaco-

logical profile, 398A3, phospholipase D activation via, in

rat mast cells, 837‘25I�pE binding, in coronary artery,

284Adenosine triphosphate, renal cellular, de-

pletion by iodoacetate and cya-

nide, in distal tubular cells, 194Adkison, K. D. K. and Shen, D. D.: Uptake

of valproic acid into rat brain is

mediated by a medium-chainfatty acid transporter, 1189

Adler, A. L., see Opgenorth, T. J., 473

Adrenal chromaffin cells, ascorbic acidtransport into, palytoxin effects,

996Adrenoceptors

alpha, myocardial, ontogenic differencesin functions of, 1155

betaand inositol phosphate generation, in

pregnant rat myometrium, 130

renin secretory response to, phos-phodiesterase IV inhibitor rolip-ram and, 1073

stimulation, canine stomach, hista-mine release and, 984

Agmatine, imidazoline receptors and, in

blood vessels, 1272Agnati, L. F., see De Gennaro Colonna, V.,

795Alaoui-Jamali, M., see Wang, T., 1169Albumin, bupivacaine binding, human,

109Alcohol, see also Ethanol

tolerance, single exposure to combinedethanol and arginine8-vasopres-sin, 1283

Aldose reductase inhibitor, effects on mo-

tor nerve conduction, autonomiccardiac function, and nerve bloodflow, vs propionyl-L-carnitine, inrats with diabetes, 49

Alendronate, long-term

general safety and biomechanical prop-

erties of bone, in adult dogs, 271histomorphometric analysis of L5 verte-

brae, in adult dogs, 277Ali, H., Choi, 0. H., Fraundorfer, P. F.,

Yamada, K., Gonzaga, H. M. S.and Beaven, M. A. : Sustained ac-tivation of phospholipase D viaadenosine A3 receptors is associ-ated with enhancement of anti-gen- and Ca2�-ionophore-inducedsecretion in a rat mast cell line,837

Ali, M., Gawin, A. Z. and Baraniuk, J. N.:

Effects of bombesin family pep-tides and antagonists on guineapig nasal mucosal secretion, 1266

Alkana, R. L., see Davies, D. L., 667

A.lmazan, G., see Deng, X. F., 1155A.LN, see Alendronate

Alpha-a-acid glycoprotein, bupivacainebinding, human, 109

Alprazolam, effects on learning, monkeys

and rats, 1111Alternation behavior, spontaneous, dizo-

cilpine-induced, nitric oxide ef-fects in, in mice, 460

Amino acid modifying agents, and 12-imidazoline binding sites, 359

-y-Aminobutyric acidA receptorsdecreases in coupling sites, 519 cells, 882

striatal, effects ofrepeated cocaine injec-

tions, 10024-Amino- 1-hydroxybutylidene bisphos-

phonate, see Alendronate

2-[2-(4-Amino-3-iodophenyl)ethylamino-

]adenosine, ‘251-labeled, adeno-sine receptor binding, in coronary

artery, 284( ± )-2-Amino-N-( 1-methyl-1,2-diphenyl-

ethyl)acetamide, see Remacemide

Amnesia, dizocilpine-induced, nitric oxide

effects in, in mice, 460Amphetamine, stimulant sensitization,

phospholipase A2 mechanisms in,1244

Anderson, D. J., see Gopalakrishnan, M.,

289Anesthetics, actions on glutamate recep-

tors, 1058Angiotensin converting enzyme inhibitors,

inhibition in vivo, determinantsof, 708

Angiotensin IIreceptor antagonists, urate transporter

interactions, in rat renal brush-border membranes, 125

tachyphylaxis to, in rat mesentery invivo, 13

Animal models, of Parkinson’s disease,

ABT-431 effects in, 150

Antiarrhythmic drugsclass III, potassium channel block by,

intracellular magnesium effects,951

novel class III, dual actions, guinea pigheart, 1149

Anticoagulants, activated protein C ef-

fects, myocardial perfusion in-jury, canine, 1104

Antidepressants, long-term, effects on5-HT1D receptors, in rat midbrainraphe nuclei, 697

Antinociception

cannabinoid-induced, brain sites medi-

ating, in rats, 585cimetidine, 500

f3-endorphin systems, in periaqueductal

gray, biochemical and pharmaco-logical characterization, in rat, 65

from the periaqueductal gray, mediatedby spinal 5-hydroxytryptamine 1A

receptors, 958

induced by agonists of several receptors,cromakalim effects, 1136

morphine, nociceptive assay and, in ge-

netic models, 532supraspinal kappa opioid, 801

Antioxidants, cytoprotective actions of, in-

hibition ofreactive oxygen species

and cell injury, 1224Anxiolytics

putative mixed 5-HT1A agonist/5-HT2�2� antagonist, antipunish-ment effects, in pigeon, 388

1996 Index 1305

typical and atypical, effects on learning,

monkeys and rats, 1111

APE, see 2-[2-(4-Amino-3-iodophenyl)eth-

ylamino]adenosineAppleton, M. L., see Thornton-Manning,

J., 21Arbutin, depigmenting effects, in human

melanocytes, 765

L-A.rginine, analog effects on L-arginine-

nitric oxide pathway, in humanneutrophils and platelets, 253

Arginine8-vasopressin, ethanol combined

treatment, development of alco-hol tolerance after, rat, 1283

Arnaudeau, S., see Khac, L. D., 130Arneric, S. P., see Gopalakrishnan, M., 289

Arrhythmia, ventricular, BRL-32872 anti-arrhythmic profile, 637

Asaad, M. M., see Seymour, A. A., 708

Ascorbic acid, uptake, palytoxin effects,

bovine adrenal chromaffin cells,

996Asin, K. E., see Shiosaki, K., 150Astrocytoma, TXA2 receptor desensitiza-

tion in, in 1321N cells, 829Atrial natriuretic peptide, secretion,

erythropoietin stimulation of, rat

cardiac atrium, 1162Atrium, rat, atrial natriuretic peptide se-

cretion, erythropoietin stimula-tion of, 1162

Auer-Barth, S., see Leist, M., 968Autoradiography

MDMA-induced serotonin deficits, 855

NPY and CGRP modulation of sigma la-beling, in mouse brain, 223

Back, D. J., see Tjia, J. F., 912Baclofen, antinociception induced by, cro-

makalim effects, 1136Bader, J. P., see McMahon, J. B., 298Baeyens, J. M., see Oca#{241}a,M., 1136Baez, M., see Wainscott, D. B., 720

Balena, R., Markatos, A., Seedor, J. G.,Gentile, M., Stark, C., Peter, C. P.and Rodan, G. A. : Long-termsafety of the aminobisphospho-

nate alendronate in adult dogs.II. Histomorphometric analysis ofthe L5 vertebrae, 277

Banick, P. D., see Chen, Q., 929Baraldi, P. G., see Zocchi, C., 398Baraniuk, J. N., see Mi, M., 1266Barker, L. A., see Li, B. Y., 500Barnette, M. S., see Manning, C. D., 810Barrett, R. J., see Martin, P. L., 490Barrios, M., see Oca#{241}a,M., 1136Bartoszyk, G. D., Harting, J. and Minck,

K.-O.: Roxindole:

cological profile of a dopamine D2autoreceptor agonist, 41

Baruchel, S., see Wang, T., 1169Basbaum, A. I., see Gogas, K. R., 801Batist, G., see Wang, T., 1169Bauman, J. L., see Liu, D., 568Baumann, H., see Yoo, S. D., 918BAY X1005, myocardial protection by, 335Beaven, M. A., see Au, H., 837

Beck, G., see Ohlstein, B. H., 609Behavior

defensive-withdrawal, acute HU-210 ef-

fects on, mediation by corticotrop-in-releasing factor, in rats, 56

diazepam effects, hyperbaric antago-nism, in mice, 667

Behavioral sensitization, cocaine, x-opioidagonist effects on, 545

Bejanian, M., see Davies, D. L., 667

Belknap, J. K., see Mogil, J. S., 532Benjamin, C. W., see Taylor, B. M., 1224Benzodiazepine, chronic exposure, alloste-

ric uncoupling after, GABA recep-tor subtypes, 882

Benzodiazepine receptors, activity, viga-batrin modulation of, baboon, 977

Berger, S. P., see Reid, M. S., 1244

Bergman, J., Spealman, R. D., Madras, B.

K. and Rosenzweig-Lipson, S.:Agonist efficacy and the behav-

ioral effects of dopamine D1receptor ligands: Drug interac-tion studies in squirrel mon-keys, 942

Bernat, A., see Herbert, J. M., 1030Berti, F., see Rossoni, G., 335Bhatt, R. K., see Powell, W. S., 728Bianchi, B., see Shiosaki, K., 150Bigelow, G. E., see Eissenberg, T., 449Bile acid, multispecific transporter, drug

and steroid clearance, mamma-han liver, 891

Billingsley, M. L., see Thompson, T. A.,1201

Biphasic kinetics, theophylline, humanliver microsomes, 912

Birkett, D. J., see Tassaneeyakul, W., 101Bitar, K. N., Kothary, S. and Kothary, P.

C.: Somatostatin inhibits bomb-esin-stimulated Gi-protein via its

own receptor in rabbit colonicsmooth muscle cells, 714

Bixier, M. A., see Winsauer, P. J., 1 111

Blier, P., see Pi#{241}eyro, G., 697

Blood-brain barrierdouble-enkephalin analog, halogenated

derivatives and, 1049

[3H]-biotinylated phosphorothioate oh-godeoxynucleotide transport, 206

valproic acid uptake, medium-chainfatty acid transporter mediation

of, 1189Blood flow, nerve, effects of PCAL vs al-

dose reductase inhibitor on, inrats with diabetes, 49

BMS-180448, effects on postischemic re-

covery of contractile function, indogs, 380

Boado, R. J., see Wu, D., 206B#{246}hm,M., see Schwinger, R. H. G., 1180

Bolger, M. B., see Davies, D. L., 667

Bombesin, antagonists and, nasal mucosalsecretion and, guinea pig, 1266

Bone, biomechanical properties, with long-term alendronate, in adult dogs,271

Bonhomme, M., see Bril, A., 637Born, S. L., see Kraner, J. C., 258Bossuyt, X., MUller, M., Hagenbuch, B.

and Meier, P. J.: Polyspecific drugand steroid clearance by an or-ganic anion transporter of mam-mahian liver, 891

Bottlaender, M., see Schmid, L., 977

Bottorff, M. B., see Ujhelyi, M. R., 683

Bouchard, P., Roman, F., Junien, J.-L. andQuirion, R.: Autoradiographic ev-idence for the modulation of in

vivo sigma receptor labeling byneuropeptide Y and calcitonin

gene-related peptide in the mousebrain, 223

Boundy, B. A., Lu, L. and Mohinoff, P. B.:Differential coupling ofrat D2 do-pamine receptor isoforms ex-pressed in Spodoptera frugiperdainsect cells, 784

Boyd, M. R., see McMahon, J. B., 298BQ123, atrial natnuretic peptide secre-

tion and, rat cardiac atrium, 1162Brain

perfusion, valproic acid, fatty acid trans-

porter mediation of, 1189sigma receptors, in vivo labeling, modu-

lation by NPY and CGRP, in

mouse, 223

sites mediating cannabinoid-induced

antinociception, in rats, 585Breese, G. R., see Yang, X., 482Brett, C. M., see Chung, S.-J., 676Bril, A., Gout, B., Bonhomme, M., Lan-

dais, L., Faivre, J.-F., Linee, P.,Poyser, R. H. and Ruffolo, R. R.,Jr. : Combined potassium and cal-cium channel blocking activitiesas a basis for antiarrhythmic effi-cacy with low proarrhythmic risk:Experimental profile of BRL-32872, 637

Britton, D. R., see Shiosaki, K., 150BRL-32872, antiarrhythmic profile, 637

Brodie, M. S., see Trifunovi�, R. D., 342-a-Bromoisovalerylurea, conjugation, se-

hective inhibition of, 923Brouilhet, E., see Schmid, L., 977Brouwer, W. G., see McMahon, J. B., 298Brush-border membranes, All antagonist-

urate transporter interactions, in

rat kidney, 125Bryant, C. M., see Endemann, G., 5Buccellati, C., see Rossoni, G., 335Buckheit, R. W., Jr., see McMahon, J. B.,

298Bupivacaine, protein binding, human, 109Buprenorphine, physical dependence, in

humans, 449

Burnett, V. L., see Kraner, J. C., 258Burnstock, G., see King, B. F., 93Buspirone

antipunishment effects, in pigeon, 388effects on learning, monkeys and rats,

1111Bustamante, D., Paeile, C., Willer, J.-C.

and Le Bars, D.: Effects of intra-venous nonsteroidal antiinflam-

matory drugs on a C-fiber reflexelicited by a wide range of stimu-lus intensities in the rat, 1232

Cadmium chloride, hepatotoxicity, metal-lothionein role in, 1216

Calcineurin, inhibition by FK-506 analogs,

mixed agonistiantagonist activ-ity, 1078

Calcitonin gene-related peptide, modula-tion of sigma labeling by, inmouse brain, 223

Calciumcytosohic levels, LTB4 metabolite effects

on, 728

homeostasis, lipid A effects on, in renal

proximal tubules, 555indolactam-mediated contractions and,

resistance vessels, 867influx

1306 Index Vol. 276

and beta adrenergic receptor activa-

tion, in pregnant rat myome-trium, 130

carbamazepine blockade, in rat cere-bellar granule cells, 143

intracellular, vasorehaxing action of ru-taecarpine, vascular smooth mus-

cle and endothehial cells, 1016sensitization, by MCI-154, in guinea pig

heart, 433transients, MCI-154 effects on, in

guinea pig heart, 433Calmodulin, binding, ethanol inhibition,

glucocorticoid antagonism, 578

Calzadilla, S. V., see Opgenorth, T. J., 473Campbell, I. G. and Feinberg, I.: Noncom-

petitive NMDA channel blockadeduring waking intensely stimu-

hates NREM 5, 737

Cannabinoid, antinociceptive effects,brain sites mediating, in rats, 585

Cannabinoid receptors, CB1, immune ac-tivation and, 776

Cantor, C. R., see Hnatowich, D. J., 326Cao, L. S., see Mazoit, J. X., 109Capasso, A., Di Guannuario, A. , Loizzo, A.,

Pieretti, S., Sagratelha, S. andSorrentino, L. : Dexamethasoneselective inhibition ofacute opioid

physical dependence in isolated

tissues, 743

Carbamazepine, calcium influx blockadeby, in rat cerebellar granule cells,

143Cardiac function, autonomic, effects of

PCAL vs aldose reductase inhibi-

tor on, in rats with diabetes, 49Cardiovascular system, moxonidine, nh-

menidine and clonidine effects on,

imidazohine receptor interactions,in rabbits, 411

Cathow, J., see Ring, B. J., 658Cella, S. G., see De Gennaro Cohonna, V.,

795

Central nervous system, opioid receptors,effects in acute morphine immu-

nomoduhation, in rats, 626Cerebellar granule cells, Ca� � influx, car-

bamazepine blockade, in rat, 143Cerebral ischemia, focal, NBQX neuropro-

tection in, dose-response study, inrat, 1

Cerebrospinal fluid, saturable taunine dis-position in, in rat, 676

Cerebrum, neurogenic vasodilation, inhi-

bition by L-glutamine and NOS,353

Cenimele, B. J., see Ring, B. J., 658C-fiber reflex, wide range of stimulus in-

tensities, intravenous nonsteroi-

dal antiinflammatory drug ef-fects, rat, 1232

CGS 27830, binding properties, 74

CGS 18102A, antipunishment effects, inpigeon, 388

Chan, C. K. S., Sannajust, F. and Head, G.A.: Role of imidazoline receptorsin the cardiovascular actions ofmoxonidine, rilmenidine andclonidine in conscious rabbits,411

Chassaing, G., see Sagan, S., 1039

Chastain, M., see Hahn, R. A., 1104Chemtob, S., see Deng, X. F., 1155Chen, C-F., see Wang, G.-J., 1016

Chen, F. Y., see Lee, T. J.-F., 353Chen, J., see Graham, S. H., 1Chen, L. Y. and Mehta, J. L.: Variable

effects of L-arginine analogs on L-

arginine-nitric oxide pathway inhuman neutrophihs and plateletsmay relate to different nitric ox-ide synthase isoforms, 253

Chen, Q., Banick, P. D. and Thom, S. R.:Functional inhibition of rat pohy-

morphonuchear leukocyte B2 inte-grins by hyperbaric oxygen is as-sociated with impaired cGMP

synthesis, 929

Chen, X., see Wang, T., 1169Chen, Z., see Lash, L. H., 194Ch#{233}ramy, A., Godeheu, G., L’Hirondel, M.

and Glowinski, J.: Cooperative

contributions of chohinergic andNMDA receptors in the presynap-tic control of dopamine releasefrom synaptosomes of the rat stri-

atum, 616Chiba, S., see Imamura, H., 467

Chin, M. H., Cioffi, C. L., Garay, M.,Neale, R. F., Shetty, S. S., Del-

Grande, D., Mugrage, B., Sills, M.

A. and Lipson, K. E.: The unusualbinding properties ofthe endothe-lin receptor antagonist CGS

27830 distinguishes receptor/

agonist interactions, 74Chinese hamster ovary cells, human NK-1

receptors, tachykinin peptide ef-fects, 1039

Chinese herbal remedies, T2, IL-2 tran-scription suppression by, 316

Chiou, W. J., see Opgenorth, T. J., 473Chiu, N., Park, I. and Reid, I. A.: Stimu-

lation of remn secretion by thephosphodiesterase IV inhibitorrolipram, 1073

Chlordiazepoxide, effects on learning,monkeys and rats, 1111

Chloride current, acetylchohine-inducedoscillations, in swine tracheal

smooth muscle cells, 178

N-(2-Chloroethyh)-4-piperidinyl dipheny-

hacetate, quarternary transfor-mation products, muscaninic re-

ceptor binding, 405

N-(3-Chhoropropyl)-4-piperidinyh dipheny-

lacetate, quarternary transfor-mation products, muscarinic re-ceptor binding, 405

Choi, 0. H., see Ali, H., 837

Choo, K. H. A., see Liu, J., 1216Chou, C., see Low, R., 855

Chou, C.-J., see Wang, G.-J., 1016Christie, M. J., see Osborne, P. B., 137

Chuang, D.-M., see Hough, C. J., 143Chung, S.-J., Ramanathan, V. K., Brett, C.

M. and Giacomini, K. M.: Satura-ble disposition of taurine in therat cerebrospinal fluid, 676

Ciceni, S., see De Gennaro Colonna, V., 795

Cieshinski, L. B., see Manning, C. D., 810Cihiary ganglion, nicotimc receptor reduc-

tion by nereistoxin, whole chick

studies, 169Cimetidine

antinociceptive properties, 500uptake into syncytial microvillus mem-

brane vesicles, in human termplacenta, 219

Cioffi, C. L., see Chin, M. H., 74Cipris, S., see Pasyk, E. A., 690L-Citrulhine, reversal of L-glutamine and

NOS inhibition of cerebral neuro-

genic vasodilation by, 353Clomipramine, effects on ethanol-induced

excitation of ventral tegmentalarea dopaminergic neurons invitro, 34

Chonidineantinociception induced by, cromakahim

effects, 1136cardiovascular effects, imidazohine re-

ceptor interactions, in rabbits,

411growth hormone function effects, in

adult male rat, 795pretreatment, effects on naloxone-pre-

cipitated opiate withdrawal, 1128

Cocaineimmunosuppression induced by, metab-

ohism by cytochrome P-450 and,

1257

lidocaine interactions, 568

modification of serotonin responses by,

rat dorsolateral septal nucleusneurons, 1292

repeated administration, locomotor ac-tivity and, C57BL/6 mice, 904

repeated injections, effects on striatalGABA receptors, 1002

sensitization, K-opioid agonist effects on,545

stimulant sensitization, phosphohipase

A2 mechanisms in, 1244Coe, I. R., Dohrman, D. P., Constanti-

nescu, A., Diamond, I. and Gor-don, A. S.: Activation of cyclic

AMP-dependent protein kinase

reverses tolerance of a nucleosidetransporter to ethanol, 365

Cohen, J., see Porat, 0., 1162Cohen, M. L., see Cox, D. A., 1095Colbert, J., see Ijia, J. F., 912Colon, relaxation by somatostatin, in rab-

bit, 714

Constantinescu, A., see Coo, I. R., 365Conte, B., Cutrufo, C. and Manzini, S.:

Electrocorticographic desynchro-

nization after application of vis-cerah and somatic noxious stimuliin urethane-anesthetized rats:Effect of intrathecal administra-tion of tachykinin (NK 1 or NK 2)

receptor antagonists, 212Conti, A., see Zocchi, C., 398Contractile function, postischemic recov-

ery, BMS-180448 effects on, indogs, 380

Cook, S. A., see Lichtman, A. H., 585Coronary artery

adenosine receptor ‘251-APE binding,284

5-HT-induced contractions, enhance-ment by oxidized low-density li-poprotein, 1095

Corpus striatum synaptosomes, dopaminerelease, presynaptic control bychohinergic and NMDA receptors,in rat, 616

Correa, L. D., see Sacaan, A. I., 509Corticotropin-reheasing factor, mediation

of acute HU-210 effects on defen-sive-withdrawal behavior by, inrats, 56

1996 Index 1307

Cotreau-Bibbo, M. M., see von Moltke, L.

L., 370Cox, D. A. and Cohen, M. L.: Selective

enhancement of 5-hy-

droxytryptamine-induced con-traction of porcine coronary an-

tery by oxidized low-density

hipoprotein, 1095

Crawford, C. A., see Reid, M. S., 1244

CREB, see Cyclic AMP response element-binding protein

Cr#{233}pon,B., see Herbert, J. M., 1030CRF, see Corticotropin-releasing factorCriswehl, H. E., see Yang, X., 482Cromakalim, antinociception and, 1136Cryan, J., see Dumont, F. J., 1078

Cumming, P., see Li, B. Y., 500Currens, M. J., see McMahon, J. B., 298Cutrufo, C., see Conte, B., 212Cyanide, renal cellular ATP depletion by,

in distal tubule, 194Cyclic AMP, estradioh effects on, in rat pul-

monary vascular smooth muscle

cells, 652

Cyclic AMP-dependent protein kinase, re-versal of chronic ethanol effects

by, 365

Cyclic AMP response element-binding pro-

tein, regulation by morphine, in

nucleus accumbens, 306

Cyclic guanosine monophosphate, synthe-sis, hyperbaric oxygen and neu-

trophils, 929Cychophosphamide, cytochrome P450 sup-

pression by, in rat, 258Cytochrome P450

3A1, mRNA expression, forskolin-medi-ated induction of, in rat hepato-cytes, 238

cocaine metabolism by, immunosup-pression induced by, 1257

isoforms, toluene and xylene metabo-hism, human, 101

olanzapine metabolism, 658suppression by cyclophosphamide, in

rat, 258theophylline metabolism, human liver

microsomes, 912

vaccinia-expressed, 3-methyhindole me-tabohism by, 21

Cytoprotection, gastric mucosah cells and,

1174

Daaka, Y., Friedman, H. and Klein, T. W.:Cannabinoid receptor proteinsare increased in jurkat, humanT-celh line after mitogen activa-tion, 776

Dalby, N. 0. and Thomsen, C.: Modulation

of seizure activity in mice by

metabotropic glutamate receptorligands, 516

4-DAMP, see N,N-Dimethyl-4-piperidinyl

diphenylacetateDaniel, E. E., see Pasyk, E. A., 690Davies, D. L., Bejanian, M., Parker, E. S.,

M#{248}rland,J., Bolger, M. B. and Al-kana, R. L.: Low level hyperbaric

antagonism of diazepam’s loco-motor depressant and anticonvuh-sant properties in mice, 667

Davies, M. P., Freeman, L. C. and Kass, R.S. : Dual actions of the novel classIII antiarrhythmic drugNE-10064 on delayed potassiumchannel currents in guinea pig

ventricular and sinoatnial node

cells, 1149

Davis, L. S., see Tao, X., 316Davis, M. J., see Miniel, V., 867

Davis, T. P., see Abbruscato, T. J., 1049

Davis-Cox, M. I., Fletcher, T. L., Turner, J.N., Szarowski, D. and Sham, W.:

Three-day exposure to how-doseethanol alters guanine nucleotidebinding protein expression in thedeveloping rat hippocampus, 758

Dayton, B. D., see Opgenorth, T. J., 473

Defensive-withdrawal behavior, acuteHU-210 effects on, mediation bycorticotropin-releasing factor, inrats, 56

De Gennaro Cohonna, V., Zohi, M., Settem-brim, B. P., Ciceni, S., De Marco,

A., Cella, S. G., Agnati, L. F. andMuller, E. E.: Effects ofsingle and

short-term administration of

clonidine on hypothalamic-pitu-itary somatotropic function of theadult male rat: An in situ hybrid-

ization study, 795

Dejneka, N. S., see Thompson, T. A., 1201DeiGrande, D., see Chin, M. H., 74De Marco, A., see De Gennaro Colonna, V.,

795

Deng, X. F., Chemtob, S., Almazan, G. andVarma, D. R.: Ontogenic differ-ences in the functions of myocar-

dial alpha1 adrenoceptor sub-types in rats, 1155

Dependence, see also Tolerancephysical

acute opioid, dexamethasone effectson, 743

buprenorphine, in humans, 449

Desensitization, TXA� receptor, in 1321Nhuman astrocytoma cells, 829

Desipramine, altered disposition and anti-depressant activity, transgenicmice, 918

Dewey, M. J., see Yoo, S. D., 918

Dexamethasone, effects on acute opioidwithdrawal, 743

Diabetes, motor nerve conduction, auto-

nomic cardiac function, and nerveblood flow in, effects of PCAL vsaldose reductase inhibitor on, inrats, 49

Diabetes insipidus, lanreotide activity in,

rat, 875

Diagne, A., see Pardridge, W. M., 246Diamond, I., see Coe, I. R., 365Diazepam , hyperbaric antagonism, in

mice, 6679,10-Didehydro-N-(2-propynyl)-6-methyh-

ergohine-8b-carboxamide, seeLEK 8804

Didomenico, S., see Shiosaki, K., 150Di Guannuanio, A., see Capasso, A., 743meso-1,4-Dihydro-5-methoxycarbonyl-2,6-

dimethyl-4-(3-nitrophenyl)-3-pynidine carboxyhic acid anhy-dnide, see CGS 27830

2,3-Dihydroxy-6-nitro-7-suhfamoyl-benzo(F) quinoxahine, neuroprotectiveeffects in focal cerebral ischemia,

dose-response study, in rat, 1Dildy-Mayfield, J. E., Eger, E. I., II and

Harris, R. A.: Anesthetics pro-duced subunit-selective actionson glutamate receptors, 1058

N-(3,4-Dimethoxyphenyh)-N-[3[2-(3,4-di-methoxyphenyh)ethyh]propyl]-4-nitrobenzamide hydrochloride,see BRL-32872

N,N-Dimethyh-4-pipenidinyh diphenyhac-etate, analogs, muscannic recep-tor binding, 405

Dingaan, B., see Farhat, M. Y., 652Dionisotti, S., see Zocchi, C., 398Discrimination, see Drug discrimination

Dixon, D. B., see Opgenorth, T. J., 473Dizocihpine

effects on non-REM b EEG, 737-induced amnesia, nitric oxide effects in,

in mice, 460

DNA, esmTc4abeled phosphodiester vs

phosphorothioate, in vitro and inmice, 326

Dohrman, D. P., see Coe, I. R., 365Dol, F., see Herbert, J. M., 1030Donevan, S. D., see Subramaniam, S., 161Donnelly-Roberts, D., see Gopalakrishnan,

M., 289Dopamine

D1 receptor higands, agonist efficacy andbehavioral effects, 942

D2 receptor coupling, in S. frugiperdainsect cells, 784

release from synaptosomes, presynapticcontrol by chohinergic and NMDAreceptors, in rat striatum, 616

ventral tegmentah area neurons, etha-noh-induced excitation of, effectsof chomipramine on, in vitro, 34

Dopamine receptorsD1

effects in squirrel monkeys, 942persistent activation of, prolonged re-

ceptor desensitization and, 1022Dopamine reuptake inhibitors, locomotor

activity and, C57BL’6 mice, 904Dorsal horn neurons, nociceptive, periaq-

ueductal gray-induced inhibitionof, 5-HT3 receptors and, in rats,116

Dorso, C. R., see Seymour, A. A., 708

Dorsolaterah septah nucleus, modificationof serotonin responses in, acute

and chronic cocaine, rat, 1292Douglas, J. S., see Rhoden, K. J., 897Drug abuse, methcathione, effects on

monoaminergic systems, 1066

Drug conjugation, hepatic, total paren-terah nutrition effects on, in rats,602

Drug discrimination, nalbuphine, in rhe-sus monkeys, 523

Drug interaction studies, dopamine D1 re-ceptor higands, squirrel monkeys,942

Dunn, S. X., see von Moltke, L. L., 370

Duman, R. S., see Widnell, K. L., 306Dumont, F. J., Ok, H., Lin, S., Kastnen, C.

A., Cryan, J., Martin, M. M.,Wiederrech, G. and Staruch, M.J.: Mixed agonist/antagonist ac-tivity ofan FK-506-related immu-nosuppressant: Biological andbiochemical characterization,1078

Dunlop, J. L., see Sacaan, A. I., 509Dunn, C., see Yue, G., 265DX 9065A, effects, factor Xa, 1030Dykstra, L. A., see Fecho, K., 626

E-4031, vagolytic effects, in dogs, 467

1308 Index Vol. 276

Eddy, E. P., see Ohlstein, E. H., 609Edwards, J. W., see Tassaneeyakuh, W.,

101

Edwards, R. M., Trizna, W., Stack, E. J.and Weinstock, J.: Interaction ofnonpeptide angiotensin II recep-tor antagonists with the urate

transporter in rat renal brush-

border membranes, 125

Eger, E. I., II, see Dildy-Mayfiehd, J. E.,

1058

Ehhert, F. J., Oliff, H. S. and Griffin, M. T.:

The quarternary transformationproducts of N-(3-chloropropyl)-4-piperidinyl diphenylacetate and

N-(2-chloroethyl)-4-pipenidinyl

diphenylacetate have differential

affinity for subtypes of the mus-carinic receptor, 405

EHNA, see Erythro-9-(2-hydroxy-3-nony-l)adenine

Eissenberg, T., Greenwald, M. K., John-son, R. E., Liebson, I. A., Bigelow,

G. E. and Stitzer, M. L.: Bu-prenorphine’s physical depen-dence potential: Antagonist-pre-cipitated withdrawal in humans,449

Electrocorticographic desynchronization,

effects of intrathecal tachykininson, in rats, 212

Ehectroencephahography, non-REM b, MK-

801 effects on, 737

Ellens, H., see Ohlstein, E. H., 609Elliott, J. D., see Ohlstein, E. H., 609Embolus imaging, two-step, galactose-

modified streptavidin-GC4 MAbconjugates for, 770

Endemann, G., Feng, Y., Bryant, C. M.,Hamilton, G. S., Perumattam, J.,Mewshaw, R. E. and Liu, D. Y.:Novel anti-inflammatory com-pounds prevent CD11b/CD18,aMP2 (Mac-1)-dependent neutro-phil adhesion without blocking

activation-induced changes inMac-i, 5

�-Endorphin, antinociceptive systems,periaqueductal gray, biochemicaland pharmacological character-ization, in rat, 65

Endothehial cells, K� channels in, VIP ef-

fects on, mediation by G protein,

690Endothehin receptors, antagonist SB

217242, pharmacological charac-

terization, 609EndothehinA receptors

antagonist A-127722, pharmacological

characterization, 473nociception mediation by, in mice, 647

EndothehinB receptors, nociception media-tion by, in mice, 647

Enflurane, actions on glutamate recep-tors, 1058

Enkephahin analog, blood-to-central ner-vous system entry, 1049

Epibatidine, effects on neurotransmitterrelease, in rats, 509

Erdmann, E., see Schwinger, R. H. G.,

1180Erythro-9-(2-hydroxy-3-nonyh)adenine,

hypoxic pulmonary vasoconstric-

tion reversal by, in rat hung, 752

Erythropoietin, stimulation, atrial natri-

uretic peptide secretion, rat car-diac atrium, 1162

Estradiol, effects on cAMP, in rat pulmo-nary vascular smooth musclecells, 652

Ethanolarginine8-vasopressin combined treat-

ment, development of alcohol toh-erance after, rat, 1283

chronic, tolerance to, reversal by cAMP-dependent protein kinase, 365

excitatory effects on ventral tegmentalarea dopaminergic neurons, ef-fects of clomipramine on, in vitro,34

glucocorticoid interactions, 578

low-dose, effects on guanine nucleotidebinding protein, in developing rathippocampus, 758

(±)-N-[(E)-4-Ethyl-3-[(Z)-hydroxyimino]-6-methyl-5-nitro-3-heptenyhl-3-pyridinecarboxamide, seeFR146801

(± )-(E)-4-Ethyl-2-[(E)-hydroxyiminol-5-

nitro-3-hexenamide, see FK409(±)-[(E)-4-Ethyl-3-[(Z)-hydroxyimino]-5-

nitro-3-hexenyl)-3-pynidinecar-boxamide, see FR144420

Factor Xa, DX 9065A inhibition of, 1030Faivre, J.-F., see Bril, A., 637Falck, J. R., see Powell, W. S., 728Fan, N. Y.-T., Powers, A. and Stier, C. T.,

Jr.: Lack of antidiuretic activityof hanreotide in the diabetes in-sipidus rat, 875

Farhat, M. Y., Abi-Younes, S., Dingaan,B., Vargas, R. and Ramwell, P.W. : Estradiol increases cyclicadenosine monophosphate in ratpulmonary vascular smooth mus-

cle cells by a nongenomic mecha-msm, 652

Farley, J. M., see Liu, X., 178Fatty acids, medium-chain, mediation of

valproic acid into rat brain, 1189

Fecho, K, Maslonek, K A., Dykstra, L. A.and Lysle, D. T. : Assessment ofthe involvement of central ner-vous system and peripheral opi-

oid receptors in the immuno-modulatory effects of acutemorphine treatment in rats, 626

Feigin, E., see Porat, 0., 1162Feinberg, I., see Campbell, I. G., 737Fehauer, E. E., see McMahon, J. B., 298

Feng, Y., see Endemann, G., 5FG 5974, antipunishment effects, in pi-

geon, 388Fibrin, galactose-modified streptavidin-

GC4 MAb conjugates, two-stepthrombus/embohus imaging appli-

cation, 770Fincher, T. K, see Yoo, S. D., 918

FK409, oral biological activities, 421FK-506 analogs, mixed agonist/antagonist

activity of, 1078

Fleming, W. E., see Taylor, B. M., 1224Fletcher, T. L., see Davis-Cox, M. I., 758

(2- 4-(4,4-bis(4-Fluorophenyh)butyl)- 1-

piperazinyl)-3-pynidinecarboxyhic

acid, see FG 5974Fogarasi, M., see Hnatowich, D. J., 326Folco, G. C., see Rossoni, G., 335

Follicular oocytes, P1 purinoceptors in, inx. laevis, 93

Fong, K-L., see Ohhstein, E. H., 609Forskohin, induction ofCYP3A1 mRNA ex-

pression by, in rat hepatocytes,238

FR144420, oral biological activities, 421FR146801, oral biological activities, 421France, C. P., see Gerak, L. R., 523Franklin, M. R., see Raftogianis, R. B., 602Fraundonfer, P. F., see Ahi, H., 837

Freel, R. W., see Hatch, M., 187

Freeman, L. C., see Davies, M. P., 1149

Friedman, H., see Daaka, Y., 776Fukuda, M., see Maeda, K, 765Fukuyama, S., see Rita, Y., 421

Furukawa, S., see Saita, K., 231Furukawa, Y., see Imamura, H., 467Furukawa, Y., see Saita, K., 231Fuseau, C., see Schmid, L., 977

GABA, see y-Aminobutyric acid

Gahactose-modified streptavidin-GC4

MAb conjugates, two-step throm-bus/embolus imaging application,

770

Galinsky, R. E., see Raftogianis, R. B., 602Gallager, D. W., see Primus, R. J., 882Gallagher, J. P., see Simms, D., 1292

Ganghion, ciliary, nicotinic receptor reduc-tion by nereistoxin, whole chickstudies, 169

Gao, X.-M., see Hough, C. J., 143Garay, M., see Chin, M. H., 74Gargalidis-Moudanos, C., see Tesson, F.,

359Gastric mucosah cells, cytoprotection and,

1174

Gastrin-releasing peptide, antagonistsand, nasal mucosah secretion and,guinea pig, 1266

Gawin, A. Z., see Mi, M., 1266Gehrke, L. J., see Opgenorth, T. J., 473Genetic models of opiate antinociception,

morphine sensitivity in, nocicep-tive assay and, 532

Gentile, M., see Balena, R., 277

Gerak, L. R. and France, C. P.: Discrimi-native stimulus effects of nalbu-phine in rhesus monkeys, 523

Gerber, J. G., see Payne, N. A., 984

Giacomini, K. M., see Chung, S.-J., 676Gibb, J. W., see Gygi, M. P., 1066Gillespie, T., see Ring, B. J., 658Glavin, G. B., Szabo, S., Johnson, B. R.,

Xing, P. L., Morales, R. E., Ple-bani, M. and Nagy, L.: Isolatedrat gastric mucosal cells: Optimalconditions for cell harvesting,measures of viability and directcytoprotection, 1174

Glennon, R. A., see Young, R., 594Glowinski, J., see Cheramy, A., 616Glucocorticoids, ethanol interactions, 578

Glutamate receptorsanesthetic actions on, 1058metabotropic higands, modulation of sei-

zures by, in mice, 516NMDA, subunits, striatal motor regula-

tion by, 342L-Ghutamine, inhibition of cerebral neuro-

genic vasodilation by, 353Glutathione

isoenzyme-selective inhibition of conju-

gation, rat, 923

1996 Index 1309

modulation by a cysteine pro-drug, en-hancement of tumor response,1169

Glycoprotein, alpha-i-acid, actions of imi-

pramine and, transgenic mice,918

Godeheu, G., see Cheramy, A., 616Gogas, K. R., Levine, J. D. and Basbaum,

A. I.: Differential contribution ofdescending controls to the antino-

ciceptive actions ofkappa and muopioids: An analysis of formalin-

evoked c-fos expression, 801Gonzaga, H. M. S., see Ali, H., 837

Gonzalez, F. J., see Thornton-Manning, J.,21

Gopalakrishnan, M., Monteggia, L. M.,

Anderson, D. J., Mohinari, E. J.,Piattoni-Kaplan, M., Donnelly-Roberts, D., Arneric, S. P. and

Sullivan, J. P.: Stable expression,pharmacologic properties andregulation ofthe human neuronalnicotinic acetylchohine a4f32 recep-tor, 289

Gordon, A. S., see Coe, I. R., 365Gout, B., see Bril, A., 637G protein

effects on 5-HT1D receptors, in rat mid-brain raphe nuclei, 697

mediation of VIP effects by, 690Graham, S. H., Chen, J., Lan, J. Q. and

Simon, R. P. : A dose-response

study of neuroprotection using

the AMPA antagonist NBQX inrat focal cerebral ischemia, 1

Gravel, S., see Powell, W. S., 728Greenblatt, D. J., see von Mohtke, L. L.,

370

Greene, J. R. T. and Mason, A.: Effects ofsomatostatin and related pep-tides on the membrane potentialand input resistance of rat yen-tral subicular neurons, in vitro,426

Greenwald, M. K., see Eissenberg, T., 449Griffin, M. T., see Ehlert, F. J., 405Grinnell, B. W., see Hahn, R. A., 1104Grover, G. J., Parham, C. S., Whigan, D.

B. and Mitroka, J. G. :180448, a novel glyburide-revers-

ible cardioprotective agent, en-

hances postischemic recovery of acontractile function in dogs, 380

Growth hormone

chonidine effects on, in situ hybridiza-tion study, in adult male rat, 795

lanreotide, hack of antidiuretic activityin diabetic rat, 875

Guanine nucheotide binding protein, low-

dose ethanol effects on, in devel-oping rat hippocampus, 758

Gulakowski, R. J., see McMahon, J. B., 298Gygi, M. P., Gibb, J. W. and Hanson, G. R.:

Methcathinone: An initial studyof its effects on monoaminergicsystems, 1066

Hagenbuch, B., see Bossuyt, X, 891Hahn, R. A., MacDonald, B. R., Chastain,

M., Grinnell, B. W. and Simpson,P. J.: Evaluation of activated pro-tom C on canine infarct size in anonthrombotic model of myocar-dial reperfusion injury, 1104

Hahogenation, double-enkephahin analog,blood-to-central nervous systementry, 1049

Halpert, J. R., see Kraner, J. C., 258

Hamada, Y., see Hotta, N., 49Hameedi, F. A., see Rosen, M. I., 1128Hamilton, G. S., see Endemann, G., 5Hammon, M. A., see Ring, B. J., 658Hanaoka, Y., see Saita, K., 231Hanson, G. R., see Gygi, M. P., 1066Hara, T., see Hotta, N., 49Harbon, S., see Khac, L. D., 130Hariman, R. J., see Liu, D., 568Harmatz, J. S., see von Moltke, L. L., 370Harrel, L. M., see von Moltke, L. L., 370Harris, R. A., see Dihdy-Mayfiehd, J. E.,

1058Harting, J., see Bartoszyk, G. D., 41

Hartnett, C., see Primus, R. J., 882Hasegawa, T., see Yamada, K., 460Hashefi, M., see Powell, W. S., 728Hashimoto, K., see Tao, X., 316Hashmi, M., see Rosebrough, S. F., 770

Hatanaka, K.-I., see Shimizu-Sasamata,

M., 84Hatch, M., Freel, R. W., Shahinfar, S. and

Vaziri, N. D.: Effects of the spe-cific angiotensin II receptor an-tagonist hosartan on urate ho-meostasis and intestinal urate

transport, 187Hawranko, A. A., see Monroe, P. J., 65

Hay, D. W. P., see Ohlstein, E. H., 609Hayashi, K, see Saita, K, 231Haynes, J., Jr., Kilhihea, D. W., Peterson,

P. D. and Thompson, W. J.:Erythro-9-(2-hydroxy-3-nonyl)ad-

enine inhibits cychic-3’,S’-guanosine monophosphate-stim-ulated phosphodiesterase toreverse hypoxic pulmonary vaso-constriction in the perfused rathung, 752

Head, G. A., see Chan, C. K. S., 411Heart

calcium sensitization by MCI-154 in, inguinea pig, 433

potassium current, NE-10064 actions

on, guinea pig, 1149

vagus control of, E-4031 effects on, indogs, 467

Heidbreder, Ch., see Shippenberg, T. S.,

545Hepatocytes, CYP3A1 mRNA expression,

forskohin-mediated induction of,in rat, 238

H#{233}rault, J. P., see Herbert, J. M., 1030Herbal remedies, T2, IL-2 transcription

suppression by, 316

Herbert, J. M., Bernat, A., Dol, F., Her-ault, J. P., Cr#{233}pon, B. andLormeau, J. C. : DX9065A, anovel, synthetic, selective andorally active inhibitor of FactorXa: In vitro and in vivo studies,

1030Hernandez, L., see Opgenorth, T. J., 473trans- 1 ,3,4,a5, iOb-Hexahydro 10-me-

thoxy-4-propyl-2H-( 1)benzoy-pyranoh[3,4-b]-pyridine, see CGS18102A

Hill, M. A., see Miriel, V., 867Hippocampus, guanine nucleotide binding

protein, low-dose ethanol effectson, in developing rat, 758

Hirasawa, Y., see Kita, Y., 421

Histaminegastric, pentagastrin-stimulated re-

lease, beta adrenoceptor stimula-tion effects, canine stomach, 984

homohogues, as H3 receptor ligands,

1009Histidine, regulation of 12-imidazohine

binding sites by, 359

HIV, see Human immunodeficiency virusHnatowich, D. J., Mardirossian, G., Foga-

rasi, M., Sano, T., Smith, C. L.,

Cantor, C. R., Rusckowski, M.and Winnard, P. , Jr. : Compara-tive properties of a technetium-99m-labehed single-stranded nat-ural DNA and a phosphorothioatederivative in vitro and in mice,

326

Hodges, L., see Shiosaki, K., 150

Hoeger, C., see Liapakis, G., 1089

Hohhaday, J. W., see Yoo, S. D., 918Hohhingsworth, Z. R., see Standaert, D. G.,

342Holsapple, M. P., see Jeong, T. C., 1257Hong, Y., see Shiosaki, K., 150

Hotta, N., Koh, N., Sakakibara, F., Naka-mura, J., Hamada, Y., Wakao, T.,

Hara, T., Mori, K., Naruse, K,

Nakashima, E. and Sakamoto,N.: Effect of propionyl-L-carnitine

on motor nerve conduction, auto-

nomic cardiac function, and nerveblood flow in rats with streptozo-tocin-induced diabetes: Compari-son with an aldose reductase in-

hibitor, 49

Hough, C. J., Irwin, R. P., Gao, X.-M., Ro-gawski, M. A. and Chuang, D.-M.:Carbamazepine inhibition of N-methyh-D-aspartate-evoked cal-cium influx in rat cerebehlar gran-uhe cells, 143

Hough, L. B., see Li, B. Y., 500Hoyano, Y., see Imamura, H., 467

H3 receptors, heterogeneity, histamine ho-mologues discriminating be-

tween, 1009Hruby, V. J., see Abbruscato, T. J., 1049Hsu, K., see Reid, M. S., 1244HU-210, acute effects on defensive-with-

drawal behavior, mediation by

CRF, in rats, 56Human immunodeficiency virus

infection, cationized hyperimmune im-munoghobuhin treatment of, in

hPBL-SCID mice, 246UC 38 effects against, 298

Hussain, T., Linden, J. and Mustafa, S. J.:

‘25I�pE binding to adenosine re-ceptors in coronary artery: Pho-

toaffinity labeling with 125I

azidoAPE, 284

Hydrogen-potassium-ATPase, inhibitors,relaxation of airway smooth mus-che, human and guinea pig, 897

8-Hydroxy-2-(di-n-propylamino)tetralin,see 8-OH-DPAT

5-Hydroxytryptamine

contractions induced by, porcine coro-nary artery, oxidized low-densityhipoprotein effects, 1095

MDMA-induced deficits

radiohigand binding and autoradiog-raphy studies, 855

1310 Index Vol. 276

synaptosomal uptake and tissue con-

centrations, 846

modification of responses, cocaine, rat

dorsolateral septal nucleus neu-

rons, 1292

5-Hydroxytryptamine1� receptors

agonisti5-HT�� antagonist anxiolytic

antipunishment effects, in pi-geon, 388

mediation, antinociception from theperiaqueductal gray, 958

5-Hydroxytryptamine1� receptors, regula-

tion in rat midbrain raphe nuclei,697

5-Hydroxytryptamine�2� receptors, an-

tagonist/5-HT1� agonist anxio-

lytic antipunishment effects, in

pigeon, 3885-Hydroxytryptamine25 receptors, phar-

macohogic characterization, 720

5-Hydroxytryptamine3 receptors, andperiaqueductah gray-induced in-hibition ofnociceptive dorsal hornneurons, in rats, 116

5-Hydroxytryptamine4 receptors, identifi-

cation, guinea pig stomach, 989Hyperbaric exposure, antagonism of diaz-

epam by, in mice, 667

Hypotension, moxonidine, rilmenidineand clonidine effects on, imidazo-

line receptor interactions, in rab-bits, 411

Hypothalamic-pituitary axis, somato-tropic function, clonidine effectson, in adult male rat, 795

Hypoxic pulmonary vasoconstriction, re-

versal by EHNA, in rat lung, 752

IBD, see Inflammatory bowel diseaseIL-2, seeImaging, two-step thrombus/embolus, ga-

lactose-modified streptavidin-GC4 MAb conjugates for, 770

Imamura, H., Furukawa, Y., Nakano, H.,Kasama, M. , Hoyano, Y. , andChiba, S.: Selective inhibition bya class III antiarrhythmic agent,

E-4031, of the negative chrono-tropic response to a parasympa-thetic stimulation in anesthetizeddogs, 467

Imidazohine receptorsagmatine and, in blood vessels, 1272

and cardiovascular effects of mox-

onidine, rilmenidine andclonidine, in rabbits, 411

12-Imidazohine, binding sites, amino acidmodifying agents and, 359

6-(1H-Imidazol-i-yl)-7-nitro-2,3-(H,4H)-quinoxahinedione hydrochloride,see YM9OK

Imipramine, altered disposition and anti-depressant activity, transgenicmice, 918

Immune activation, and CB1 cannabinoidreceptors, 776

Immunoglobulin, cationized hyperim-mune, phanmacokinetics, toxicityevaluation and treatment of HN-

infected hPBL-SCID mice, 246Immunomoduhation, acute morphine, in

rats, 626Immunosuppression

cocaine-induced, metabolism by cyto-chrome P-450 and, 1257

FK-506-related, mixed agonistIantago-nist activity of, 1078

Indolactam, contractions mediated by, cal-cium dependence of, resistancevessels, 867

Infection, HN, cationized hyperimmune

immunoglobuhin treatment of, in

hPBL-SCID mice, 246Inflammatory bowel disease, amelioration

by U74006F, in rats, 265

Inositol phosphates, generation, beta ad-renergic receptors and, in preg-

nant rat myometrium, 130Inotropic agents, enantioselective actions,

sodium channel activators, hu-

man myocardium, 1180Inotsume, N., see Ohtomo, T., 1143Integrmns, pohymorphonuclear leukocyte

B2 functional inhibition by hy-

perbaric oxygen, rat, 929aMP2 Integnins, upregulation, leumeclins

and, 5Interheukin-2, transcription, suppression

by T2, 316

Intestine, urate transport, hosantan effects

on, 187

Inui, K.-I., see Ohtomo, T., 1143lodoacetate, renal cellular ATP depletion

by, in distal tubule, 194Irwin, R. P., see Hough, C. J., 143Ischemia

focal cerebral, NBQX neuroprotectionin, dose-response study, in rat, 1

myocardial, contractile function recov-ery after, BMS-180448 effects on,

in dogs, 380

Ishine, T., see Lee, T. J.-F., 353Ishisu, R., see Abe, Y., 433

Isicka, A. M., see Abbruscato, T. J., 1049Isoenzymes, selective inhibition of gluts-

thione conjugation, rat, 923Isoflurane, actions on glutamate recep-

tors, 1058

Isoproterenol, stimulation, canine stom-

ach, pentagastric-stimulated his-tamine release and, 984

Jackson, E. K, see Tofovic, S. P., 13Jacoby, H. I., see Raffa, R. B., 647

Jenner, P., see Shiosaki, K., 150Jeong, T. C., Jordan, S. D., Matulka, R. A.,

Stanuhis, E. D., Park, S. S. and

Hohsapple, M. P.: Immunosup-pression induced by acute expo-sure to cocaine is dependent onmetabolism by cytoehrome P-450,1257

Johns, R. A., see Rengasamy, A., 30Johnson, B. R., see Glavin, G. B., 1174Johnson, R. E., see Eissenberg, T. , 449Jones, G. S., Jr., see Xie, Y., 169Jordan, S. D., see Jeong, T. C., 1257Junien, J.-L., see Bouchard, P., 223

Kainate, currents induced by, anesthetic

effects, Xenopus oocytes, 1058Kahant, H., see Wu, P. H., 1283Kamenka, J.-M., see Prinssen, E. P. M.,

904Kan, H., Ruan, Y. and Malik. K. U.: Local-

ization and characterization ofthe subtype(s) of muscarinic re-ceptor involved in prostacyclinsynthesis in rabbit heart, 934

Kang. Y.-S., see Pardridge, W. M., 246

Kasama, M., see Imamura, H., 467

Kass, R. S., see Davies, M. P., 1149Kastner, C. A., see Dumont, F. J., 1078Kathmann, M., see Leurs, R., 1009Kato, M., see Kits, Y., 421Kato, Y., see Kita, Y., 421Kawasaki-Yatsugi, S., see Shimizu-Sasa-

mata, M., 84Kest, B., see Mogil, J. S., 532Khac, L. D., Arnaudeau, S., Lepretre, N.,

Mironneau, J. and Harbon, S.:Beta adrenergic receptor activa-

tion attenuates the generation ofinositol phosphates in the preg-nant rat myometrium. Correla-tion with inhibition of Ca� � in-

flux, a cAMP-independentmechanism, 130

Khanapure, S. P., see Powell, W. S., 728Kidney, see also under Renal

brush-border membranes, All antago-

nist-urate transporter interac-tions, in rat, 125

Kilhilea, D. W., see Haynes, J., Jr., 752

King, B. F., Pintor, J., Wang, S., Zigan-shin, A. U., Ziganshina, L. E. andBurnstock, G.: A novel P1 purino-

ceptor activates an outward K�current in follicular oocytes of Xe-nopus laevis, 93

Rita, Y., Hirasawa, Y., Fukuyama, S., Oh-kubo, K., Kato, Y., Takamatsu,H., Ohno, M., Nishino, S., Kato,M. and Seki, J.: Oral biologicalactivities of spontaneous nitricoxide reheasers are accounted forby their nitric oxide-releasingrates and oral absorption man-

ners, 421

Klaassen, C. D., see Liu, J., 1216Klein, T. W., see Daaka, Y., 776

Kleven, M. S. and Kook, W.: Pharmacohog-

icah characterization of in vivoproperties of putative mixed5-HT1A agonist/5-HT�2� antago-nist anxiolytics. I. Antipunish-

ment effects in the pigeon, 388Kleven, M. S., see Prinssen, E. P. M., 904Koek, W., see Kieven, M. S., 388

Koek, W., see Prinssen, E. P. M., 904Koh, N., see Hotta, N., 49Komori, Y., see Yamada, K, 460Koob, G. F. , see Rodriguez de Fonseca, F.,

56Koshiya, K., see Shimizu-Sasamata, M., 84

Kostas, C., see Primus, R. J., 882Kosten, T. R., see Rosen, M. I., 1128Kothary, P. C., see Bitar, K N., 714

Kothary, S., see Bitar, K N., 714

Kraner, J. C., Morgan, E. T., Poet, T. S.,

Born, S. L., Burnett, V. L. andHahpert, J. R.: Suppression of rathepatic microsomal cytochromesP450 by cychophosphamide is cor-related with plasma thyroid hor-mone levels and displays differen-tial strain sensitivity, 258

Kreek, M. J., see Rosen, M. I., 1128Kursar, J. D., see Wainscott, D. B., 720

Kmvahue, for oxygen, of nitric oxide syn-thase, 30

Lago, A., see Ohistein, E. H., 609Lai, C. C., see Lee, T. J.-F., 353Lan, J. Q., see Graham, S. H., 1Lan#{231}a,A. J., see Wu, P. H., 1283Landais, L., see Bril, A., 637

1996 Index 1311

Lane, S. B., see Widnell, K. L., 306

Lanreotide, antidiuretic activity of, dia-

betic rat, 875

Lash, L. H., Tokarz, J. J., Chen, Z.,

Pedrosi, B. M. and Woods, E. B.:

ATP depletion by iodoacetate andcyanide in renal distal tubular

cells, 194

Lavielle, S., see Sagan, S., 1039Lazaroids, cytoprotective actions of, inhi-

bition of reactive oxygen species

and cell injury, 1224Learning, typical and atypical anxiolytic

effects, monkeys and rats, 1111

Le Bars, D. , see Bustamante, D., 1232Lee, T. J.-F., Sarwinski, S., Ishine, T., Lai,

C. C. and Chen, F. Y.: Inhibitionof cerebral neurogenic vasodila-

tion by L-glutamine and nitric ox-

ide synthase inhibitors and its re-versal by L-citrulhine, 353

LeFevour, A., see Shippenberg, T. S., 545Leist, M., Auer-Barth, S. and Wendel, A.:

Tumor necrosis factor production

in the perfused mouse liver and

its pharmacological modulation

by methylxanthines, 968

LEK 8804, antipunishment effects, in pi-geon, 388

Lepretre, N., see Khac, L. D., 130

Leukotriene B4, metabolite effects on neu-trophils, 728

Leumedins, and Mac-i upregulation, 5

Leurs, R., Kathmann, M., Volhinga, R. C.,

Menge, W. M. P. B., Schlicker, E.and Timmerman, H. : Histaminehomologues discriminating be-

tween two functional histamine

H3 receptor assays. Evidence forH3 receptor heterogeneity?, 1009

Levine, J. D., see Gogas, K. R., 801

Levine, M., see Morita, K., 996

Levofloxacin, transport, kidney epithelial

cell line, LLC-PK1, 1143

Low, R., Sabol, K. E., Chou, C., Vosmer, G.L., Richard, J. and Seiden, L. S.:Methylenedioxymethamphet-amine-induced serotonin deficitsare followed by partial recoveryover a 52-week period. Part II:

Radiohigand binding and autora-

diography studies, 855

Low, R., see Sabol, K. E., 846

Lewis, J. B., see Thompson, T. A., 1201

L’Hirondel, M., see Cheramy, A., 616

Li, B. Y., Naiwalk, J. W., Barker, L. A.,Cumming, P., Parsons, M. E. andHough, L. B.: Characterization ofthe antinociceptive properties of

cimetidine and a structural ana-

log, 500

Liapakis, G., Heoger, C., Rivier, J. and

Reisine, T. : Development of a se-

lective agonist at the somatosta-tin receptor subtype SSTR1, 1089

Lichtman, A. H., Cook, S. A. and Martin,B. R.: Investigation of brain sitesmediating cannabinoid-inducedantinociception in rats: Evidencesupporting periaqueductal gray

involvement, 585

Lidocaine, cocaine interactions, 568Liebson, I. A., see Eissenberg, T., 449

Limon, I., see Tesson, F., 359

Lin, C. W., see Shiosaki, K., 150

Lin, Q., Peng, B. and Willis, W. D.: Antino-ciception and inhibition from the

periaqueductal gray are mediatedin part by spinal

5-hydroxytryptamine1� recep-

tors, 958

Lin, Q., see Peng, Y. B., 116Lin, S., see Dumont, F. J., 1078Linden, J., see Hussain, T., 284

Linden, J., see Martin, P. L., 490Lindsay, T. J., see Ring, B. J., 658Linee, P., see Bril, A., 637Lipid A, effects on calcium homeostasis in

renal proximal tubules, 555

Lipkowski, A. W., see Abbruscato, T. J.,1049

Lipoprotein, oxidized how-density, en-hancement of 5-HT-induced con-tractions of porcine coronary ar-

tery, 1095Lipsky, P. E., see Tao, X., 316Lipson, K. E., see Chin, M. H., 74Liu, D., Hariman, R. J. and Bauman, J. L.:

Cocaine concentration-effect rela-tionship in the presence and ab-

sence of lidocaine: Evidence of

competitive binding between co-caine and hidocaine, 568

Liu, D. Y., see Endemann, G., 5Liu, J., Liu, Y., Michahska, A. E., Choo, K

H. A. and Klaassen, C. D.: Metal-lothionein plays less of a protec-

tive role in cadmium-metallothio-

nein-induced nephrotoxicity thanin cadmium chloride-induced

hepatotoxicity, 1216Liu, J.-F., see Wu, P. H., 1283Liu, X. and Farley, J. M.: Acetylchohine-

induced chloride current oscilla-

tions in swine tracheal smooth

muscle cells, 178

Liu, Y., see Liu, J., 1216Liver

drug conjugation, total parenteral nutri-tion effects on, in rats, 602

drug transport, polyspecific, 891

microsomes

theophylline metabolism in, human,

912

triazolam biotransformation, in vitro,

human, 370

septic failure, tumor necrosis factor pro-duction and methylxanthines,mouse, 968

tributylmethylammonium uptake, rat

plasma membrane vesicle stud-

ies, 561

Livi, G. P., see Manning, C. D., 810

LLC-PK1 cell line, transport of levofloxa-cm in, 1143

Lloyd, G. K., see Sacaan, A. I., 509Locomotor activity, diazepam effects on,

hyperbaric antagonism of, in

mice, 667Locus ceruleus, muscarinic and opioid cur-

rents, tetrahydro-9-aminoacri-

dine effects on, in rat neurons,

137

Loizzo, A., see Capasso, A., 743

Loring, R. H., see Xie, Y., 169

Lormeau, J. C., see Herbert, J. M., 1030

Losartan, effects on urate homeostasis

and intestinal urate transport,

187

Lu, L., see Boundy, B. A., 784

Lu, L., see Munir, M., 819Lumbar vertebrae, L5, histomorphometric

analysis, with hong-term ahendr-

onate, in adult dogs, 277Lung

hypoxic vasoconstniction, reversal byEHNA, in rat, 752

vascular smooth muscle cells, cAMP in,

estradiol effects on, in rat, 652

Luo, J., see Munir, M., 819Lyshe, D. T., see Fecho, K., 626

Mac-i, upregulation, leumedins and, 5

MacDonald, B. R., see Hahn, R. A., 1104Macleod, R. J., see Powell, W. S., 728

Maclouf, J., see Rossoni, G., 335

Madras, B. K., see Bergman, J., 942

Maeda, K. and Fukuda, M. : Arbutin:Mechanism of its depigmentingaction in human melanocyte cul-ture, 765

Magnesium, intracellular, potassium

channel block by class III antiar-rhythmic drug and, 951

Magnuson, S. R., see Opgenorth, T. J., 473Mahan, L., see Shiosaki, K., 150

Malik, K. U., see Kan, H., 934Manna, S., see Powell, W. S., 728Manning, C. D., McLaughlin, M. M., Livi,

G. P., Cieshinski, L. B., Torphy, T.J. and Bannette, M. S.: Prolongedbeta adrenoceptor stimulation up-regulated cAMP phosphodiester-

ase activity in human monocytes

by increasing mRNA and protein

for phosphodiesterases 4A and

4B, 810Manzini, S., see Conte, B., 212

Mardirossian, G. , see Hnatowich, D. J.,326

Markatos, A., see Balena, R., 277

Markel, M. L., see Ujhelyi, M. R., 683

Marsh, K. C., see Opgenorth, T. J., 473Martin, B. R., see Lichtman, A. H., 585

Martin, M. M., see Dumont, F. J., 1078Martin, P. L., Wysocki, R. J., Jr., Barrett,

R. J., May, J. M. and Linden, J.:Characterization of 8-(N-methyhi-sopropyh)amino-N6-(5’-endohy-

droxy-endonorbornyl)-9-methy-

ladenine (WRC-057i), a highly

potent and selective, non-xan-thine antagonist of A1 adenosine

receptors, 490

Maslonek, K. A., see Fecho, K., 626

Mason, A. , see Greene, J. R. T., 426Mast cells, phosphohipase D activation via

A3 receptors in, in rat, 837Mathews, W. R., see Taylor, B. M., 1224

Matsukura, S., see Saita, K., 231

Matsuyama, S., Sakiyama, H., Nei, K. and

Tanaka, C.: Identification of pu-

tative 5-hydroxytryptamine4 (5-

HT4) receptors in guinea pigstomach: The effect of TKS159, a

novel agonist, on gastric motility

and acetylchohine release, 989

Matulka, R. A., see Jeong, T. C., 1257May, J. M., see Martin, P. L., 490

Mayeux, P. R., see Proksch, J. W., 555

Maziere, M., see Schmid, L., 977

Mazoit, J. X., Cao, L. S. and Samii, K.:Binding of bupivacaine to human

serum proteins, isolated albumin

and isolated alpha-i-acid ghycop-

rotein. Differences between the

1312 Index Vol. 276

two enantiomers are partly due tocooperativity, 109

McGonigle, P., see Munir, M., 819

McHugh, T., see Xie, Y., 169

MCI-i54, calcium sensitization by, inguinea pig heart, 433

McKay, J., see Xie, Y., 169

McLaughlin, M. M., see Manning, C. D.,

810

McMahon, J. B., Buckheit, R. W., Jr., Gu-

lakowski, R. J., Currens, M. J.,

Vistica, D. T., Shoemaker, R. H.,

Stinson, S. F., Russell, J. D.,

Bader, J. P., Narayanan, V. L.,

Schultz, R. J., Brouwer, W. G.,

Fehauer, E. E. and Boyd, M. R.:

Biological and biochemical anti-

human immunodeficiency virus

activity of UC 38, a new non-

nucleoside reverse transcriptase

inhibitor, 298

McMahon, T. J., see Rosen, M. I., 1128

MDA, see 1-(3,4-Methylenedioxyphenyl)-

2-aminopropane

Medial septum, nicotinic acetylchohine re-

ceptors, 482

Mehta, J. L., see Chen, L. Y., 253Meier, P. J., see Bossuyt, X, 891

Meijer, D. K. F., see Mosehey, R. H., 561

Melanocytes, arbutin depigmenting ef-

fects, mechanism of action, 765

Mehe, P. C., see Winsauer, P. J., 1111

Melnychuk, D., see Wang, T., 1169

Menge, W. M. P. B., see Leurs, R., 1009

Menzaghi, F. , see Rodriguez de Fonseca,

F., 56

Menzaghi, F., see Sacaan, A. I., 509Merho-Pich, E. , see RodrIguez de Fonseca,

F., 56

Mesenteny, tachyphylaxis to angiotensin

II, in rat in vivo, 13

Messenger RNA, CYP3A1, expression, for-

skolin-mediated induction of, in

rat hepatocytes, 238

Mesylates, 21-aminosteroid tirilazad, IBD

amelioration by, in rats, 265

Metabotropic glutamate receptors, hi-gands, modulation of seizures by,in mice, 516

Metallothionein, protective role, cadmi-um-metallothionein-induced

nephrotoxicity, 1216

Methcathinone, effects on monoaminergicsystems, i066

Methoxamine, ontogenic differences infunction, myocardium, rat, 1155

N-Methyl-D-aspartate

channel blockade during waking, effectson NREM b, 737

-evoked Ca� � influx, carbamazepine

blockade, in rat cerebellar gran-ule cells, 143

receptors

glutamate, subunits, striatal motor

regulation by, 342

in NT2-N neurons, characterization,

819

presynaptic control of dopamine re-

lease by, in rat striatum synapto-

somes, 616

remacemide and des-glycine metabo-

hite blockade, 161

4-Methylcatechol, effects on recovery fromacrylamide neuropathy, 231

Methyhenedioxymethamphetamine, sero-

tonin deficits

radiohigand binding and autoradiogra-phy studies, 855

synaptosomal uptake and tissue concen-

trations, 846

i-(3,4-Methylenedioxyphenyl)-2-amin-opropane, R(-)- vs S(+ ) stimulus

effects, 5943-Methylindole, metabolism by vaccinia-

expressed P450 enzymes, 218-(N-Methylisopropyl)amino-N6-(5’-en-

dohydroxy-endonorbornyh)-9-methyhademne, see WRC-057i

Methylxanthine, pharmacology, tumor ne-crosis factor production and,

mouse liver, 968Mewshaw, R. E., see Endemann, G., 5Meyyappan, M., see Primus, R. J., 882Michaehides, M., see Shiosaki, K., 150Michahska, A. E., see Liu, J., 1216Microsomes, liver, triazolam biotransfor-

mation, in vitro, human, 370Mikusa, J., see Shiosaki, K, 150Miller, T., see Shiosaki, K, 150

Minck, K.-O., see Bartoszyk, G. D., 41

Miners, J. 0., see Tassaneeyakul, W., 101

Miriel, V., Zou, H., Davis, M. J., Song, J.and Hill, M. A.: Calcium depen-

dence of indolactam-mediatedcontractions in resistance vessels,867

Mironneau, J., see Khac, L. D., 130Miserendino, M. J. D., see Widnell, K. L.,

306Mitroka, J. G., see Grover, G. J., 380MK-801, see DizocilpineMogil, J. S., Kest, B., Sadowski, B. and

Behknap, J. K.: Differential ge-netic mediation of sensitivity tomorphine in genetic models of

opiate antinociception: Influenceof nociceptive assay, 532

Mohinari, E. J., see Gopalakrishnan, M.,

289

Mohinoff, P. B., see Boundy, B. A., 784

Molta, C., see Rossoni, G., 335Monoamine oxidase, I2-imidazohine bind-

ing sites, 359

Monoaminergic systems, methcathinone

effects, 1066

Monoclonal antibodies, galactose-modified

streptavidin-GC4 antifibrin con-

jugates, two-step thrombus/em-

bohus imaging application, 770

Monocytes, phosphodiesterase 4 isozymes,

810

Monopoli, A., see Zocchi, C., 398Monroe, P. J., Hawranko, A. A., Smith, D.

L. and Smith, D. J.: Biochemicaland pharmacological character-

ization of multiple /3-endorphin-ergic antinociceptive systems in

the rat periaqueductal gray, 65

Monteggia, L. M., see Gopalakrishnan, M.,289

Morales, R. E., see Glavin, G. B., 1174Morgan, E. T., see Kraner, J. C., 258Mori, K., see Hotta, N., 49Morita, K., Teraoka, K, Oka, M. and Le-

vine, M.: Inhibitory action of pa-

lytoxin on ascorbic acid transport

into cultured bovine adrenal chro-maffin cells, 996

M#{248}rland,J., see Davies, D. L., 667

Morphineacute, immunomoduhatory effects, in

rats, 626

antinociception induced by, cromakalimeffects, 1136

antinociceptive effects in genetic mod-els, nociceptive assay and, 532

CREB regulation by, in nucleus accum-bens, 306

Moseley, R. H., Smit, H., Van Solkema, B.

G. H., Wang, W. and Meijer, D. K.F.: Mechanisms for the hepaticuptake and bihiary excretion oftributylmethylammonium: Stud-ies with rat liver plasma mem-

brane vesicles, 561

Motor behavior, regulation, by NMDA glu-tamate receptor subunits, 342

Motor nerve conduction, effects of PCAL

vs aldose reductase inhibitor on,

in rats with diabetes, 49

Moxonidine, cardiovascular effects, imida-zoline receptor interactions, inrabbits, 411

Mugrage, B., see Chin, M. H., 74Mulder, G. J., see Ouwerkerk-Mahadevan,

S., 923

Muller, M., see Bossuyt, X, 891

Muller, E. E., see De Gennaro Cohonna, V.,795

MUller-Ehmsen, J., see Schwinger, R. H.

G., 1180Mulher-Peddinghaus, R., see Rossoni, G.,

335Munir, M., Lu, L., Wang, Y.-H., Luo, J.,

Wolfe, B. B. and McGonigle, P.:Pharmacological and immunolog-

ical characterization of N-methyl-

D-aspartate receptors in human

NT2-N neurons, 819

Murase, K., see Shimizu-Sasamata, M., 84Muscarinic receptors

4-DAMP analog binding, 405subtypes of, prostacyclin synthesis, rab-

bit heart, 934

tetrahydro-9-aminoacridine effects on,in rat hocus ceruleus neurons, 137

Muscle, see Smooth muscleMustafa, S. J., see Hussain, T., 284

Myocardial infarction, activated protein C

effects on infarct size, canine non-

thrombotic model, 1104Myocardial ischemia, contractile function

recovery after, BMS-180448 ef-

fects oi, in dogs, 380

Myocardium

protection by BAY Xi005, 335sodium channel activators, enantios-

elective inotropic actions of, 1180Myometrium, inositol phosphate genera-

tion, beta adrenergic receptors

and, in pregnant rat, 130

Nabeshima, T., see Yamada, K., 460

Nachshon, S., see Porat, 0., 1162Nagy, L., see Glavin, G. B., 1174Nakahata, N., see Sakai, K., 829Nakamura, J., see Hotta, N., 49Nakano, H., see Imamura, H., 467Nakano, T., see Abe, Y., 433Nakashima, E., see Hotta, N., 49Nalbuphine, discriminative stimulus ef-

fects, in rhesus monkeys, 523

Naloxone, opiate withdrawal precipitated

by, clonidine pretreatment ef-

fects, 1128

1996 Index 1313

Nalwahk, J. W., see Li, B. Y., 500Nambi, P., see Ohlstein, E. H., 609

Narayanan, V. L., see McMahon, J. B., 298

Narimatsu, A., see Abe, Y., 433Naruse, K., see Hotta, N., 49Nasal mucosa, secretion, effects of bomb-

esin family peptides and antago-

nists on, 1266Navarro, M. , see RodrIguez de Fonseca, F.,

56

NBQX, see 2,3-Dihydroxy-6-nitro-7-sulfa-moyl-benzo (F) quinoxaline

NE-i0064, dual actions, guinea pig yen-

tricular and sinoatrial node cells,1149

Neale, R. F., see Chin, M. H., 74Negretti, A., see Zocchi, C., 398Nei, K., see Matsuyama, S., 989

Nelson, D. L., see Wainscott, D. B., 720Neostriatum, motor regulation, by NMDA

glutamate receptor subunits, 342

Nephrotoxicity, Cd-metallothionein, met-

ahlothionein protective role in,

1216

Nereistoxin, metabohite, mcotinic receptor

reduction by, whole chick ciliaryganglion studies, 169

Nerve blood flow, effects ofPCAL vs aldose

reductase inhibitor on, in rats

with diabetes, 49

Nestler, E. J., see Widnell, K. L., 306Neumann, D., see Porat, 0., 1162Neurogenic vasodilation, cerebral, inhibi-

tion by L-glutamine and NOS, 353

Neurokinin 1 receptors, intrathecal antag-

onist effects on electrocortico-

graphic desynchronization, inrats, 212

Neurokinin 2 receptors, intrathecal antag-

onist effects on electrocortico-

graphic desynchronization, in

rats, 212

Neuromedin B, nasal mucosal secretion

and, guinea pig, 1266Neuropathy, acrylamide-induced, recov-

ery from, 4-methylcatechol effects

on, 23i

Neuropeptide Y, modulation of sigma ha-

beling by, in mouse brain, 223

Neurotoxicity, selective, induction of apop-tosis by organotin compounds,

i2Oi

Neurotransmitters, release, epibatidine

effects on, in rats, 509

Neutral endopeptidase 3.4.24.li, inhibi-tion in vivo, determinants of, 708

Neutrophils

L-arginine-nitnic oxide pathway, L-

arginine analog effects on, in hu-

man, 253

LTB4 metabolite effects on, 728

Mac- i-dependent adhesion, leumedinblockade, 5

Nicotinic acetylcholine receptors

a4132, expression, pharmacologic proper-ties and regulation, 289

agonist epibatidine, effects on neuro-

transmitter release, in rats, 509

neural effects in medial septum, 482

reduction by nereistoxin, whole chickciliary ganglion studies, 169

Nikai, T., see Yamada, K., 460Nikkel, A., see Shiosaki, K., 150

Nishino, S., see Kita, Y., 421

Nitric oxide

effects in dizocilpine-induced impair-

ment of spontaneous alternation

behavior, in mice, 460

spontaneous releasers, oral biologicalactivities, 421

synthesis of, L-arginine analog effects

on, in human neutrophihs and

platelets, 253

Nitric oxide synthase

inhibitors, inhibition of cerebral neuro-

genic vasodilation by, 353Kmvahue for oxygen of, 30

Nociception, endothehin-induced, in mice,647

Nociceptive assay, and morphine antinoci-ception in genetic models, 532

Nociceptive dorsal horn neurons, periaq-ueductal gray-induced inhibitionof, 5-HT3 receptors and, in rats,116

Noda, Y., see Yamada, K., 460Non-rapid eye movement sleep 8, MK-80i

effects on, 737

Nonsteroidal antiinflammatory agents, in-

travenous, effects on C-fiber re-

flex, rat, 1232Norepinephrine, ontogenic differences in

function, myocardium, rat, 1155

Novosad, E. I., see Opgenorth, T. J., 473NREM, see Non-rapid eye movement

NT2-N neurons, NMDA receptors in, char-

acterization, 819Nucleus accumbens, CREB regulation by

morphine in, 306

Oca#{241}a,M., Barrios, M. and Baeyens, J. M.:Cromakalim differentially en-hances antinociception induced

by agonists of alpha2 adrenocep-tons, y-aminobutyric acid B. Muand Kappa opioid receptors, 1136

8-OH-DPATantipunishment effects, in pigeon, 388

effects on learning, monkeys and rats,liii

Ohi, T., see Saita, K., 231

Ohizumi, Y., see Sakai, K., 829

Ohkubo, K., see Kita, Y., 421

Ohlstein, E. H., Nambi, P., Lago, A., Hay,

D. W. P., Beck, G., Fong, K-L.,Eddy, E. P., Smith, P., Ellens, H.and Elliott, J. D.: Nonpeptide en-dothehin receptor antagonists. VI:Pharmacological characterizationofSB 217242, a potent and highlybioavaihable endothehin receptorantagonist, 609

Ohmori, J., see Shimizu-Sasamata, M., 84

Ohno, M., see Rita, Y., 421Ohtomo, T. , Saito, H., Inotsume, N., Yasu-

hara, M. and Inui, K-I.: Trans-

port of levofloxacin in a kidney

epithelial cell line, LLC-PK1: In-

teraction with organic cationtransporters in apical and baso-

lateral membranes, 1143Ok, H., see Dumont, F. J., 1078Oka, M., see Morita, K., 996Okada, M., see Shimizu-Sasamata, M., 84

Ohanzapine, cytochromes P450 metabo-lism, 658

Ohiff, H. S., see Ehlert, F. J., 405Oligodeoxynucleotide, [3H]-biotinylated

phosphorothioate, pharmacoki-

netics and blood-brain barrier

transport, 206

Omeprazole, relaxation, airway smoothmuscle, human and guinea pig,

897

Omiecinski, C. J., see Sidhu, J. S., 238

Ongini, E., see Zocchi, C., 398Onishi, K., see Abe, Y., 433Ono, H., see Sakai, K., 829

Opgenorth, T. J., Adler, A. L., Cahzadilla,

S. V., Chiou, W. J., Dayton, B. D.,

Dixon, D. B., Gehrke, L. J., Her-nandez, L., Magnuson, S. R.,

Marsh, K. C., Novosad, E. I., Von

Geldern, T. W., Wessale, J. L.,Winn, M. and Wu-Wong, J. R.:Pharmacological characterization

ofA-i27722: An orally active and

highly potent ETA-selective re-

ceptor antagonist, 473

Opioid receptorsdelta, spinal, analgesic potency, in am-

phibians, 440

effects in acute morphine immunomodu-

hation, in rats, 626

kappa

agonists, effects on sensitization to co-

caine, 545

spinal, analgesic potency, in amphib-

ians, 440

supraspinal, antinociceptive effects,

801

mu, spinal, analgesic potency, in am-

phibians, 440

tetrahydro-9-aminoacridine effects on,

in rat locus ceruheus neurons, 137

Opioidswithdrawal

dexamethasone effects on, 743

naloxone-precipitated, clonidine pre-

treatment effects, 1128

Organic anions, transporter, drug and ste-roid clearance, mammalian liver,891

Organic cationshepatic transport, rat liver plasma

membrane vesicle studies, 561secretion, enhancement by urine acidifi-

cation, 683

Osborne, P. B. and Christie, M. J.: Tetra-

hydro-9-aminoacridine has mixedactions on muscarinic currents

and blocks opioid currents in rat

hocus ceruheus neurons, 137

Ouwerkerk-Mahadevan, S. , vanBoom, J.H. and Mulder, G. J.: Isoenzyme-selective inhibition of ghutathione

conjugation in vivo: Selective in-hibition of the conjugation of S-2-

bromoisovaleryhurea in the rat,

9232-L-Oxothiazohidine carboxyhate, enhance-

ment of tumor response, moduha-

tion of glutathione by, 1169

Oxygenhyperbaric, functional inhibition of rat

polymorphonuclear heukocyte B2

integrins by, 929

Kmvalue for, of nitric oxide synthase, 30

Paeile, C., see Bustamante, D., 1232

Palytoxin, inhibitory action, ascorbic acid

transport, bovine adrenal chro-maffin cells, 996

Pang, P. K. T., see Wang, G.-J., 1016Parasympathetic nervous system, stimu-

lation of, cardiac responses,E-403i effects on, in dogs, 467

1314 Index Vol. 276

Pardridge, W. M., Kang. Y.-S., Diagne, A.and Zack, J. A.: Cationized hyper-

immune immunoglobulins: Phar-

macokinetics, toxicity evaluation

and treatment of human immu-

nodeficiency virus-infected hu-

man-peripheral blood lympho-

cytes-severe combined immune

deficiency mice, 246

Pardridge, W. M., see Wu, D., 206Parenteral nutrition, total, effects on he-

patic drug conjugation, in rats,

602

Parham, C. S., see Grover, G. J., 380

Parini, A., see Tesson, F., 359

Park, I., see Chiu, N., 1073

Park, S. S., see Jeong, T. C., 1257

Parker, E. S., see Davies, D. L., 667

Parkinson’s disease

ABT-431 effects in, in animal models,

150

dopamine D1 receptor effects, receptordesensitization, studies with

A-77636, 1022

Parsons, M. E., see Li, B. Y., 500

Pasyk, E. A., Cipris, S. and Daniel, E. E.: A

G protein, not cyclic AMP, medi-ates effects of VIP on the in-

wardly K� channels in endothe-

hal cells, 690

Payne, N. A. and Gerber, J. G.: The effect

of beta adrenoceptor stimulation

of canine stomach on pentagas-

trin-stimulated histamine re-

lease, 984

PCAL, See Propionyh-L-carnitine

Pearsall, H. R., see Rosen, M. I., 1128

Pedrosi, B. M., see Lash, L. H., 194

Peereboom-Stegeman, J. H. J. C. , see Aa,

E. M. van der, 219

Peng, B., see Lin, Q., 958

Peng, Y. B., Lin, Q. and Willis, W. D.: Therole of 5-HT3 receptors in periaq-

ueductal gray-induced inhibition

of nociceptive dorsal horn neu-

rons in rats, 116

Pentagastrin, histamine release stimu-

hated by, beta adrenoceptor stim-ulation effects, canine stomach,

984

Pentoxifylhine, pharmacology, tumor ne-

crosis factor production and,

mouse liver, 968

Periaqueductal grayantinociception and inhibition from, me-

diated by spinal 5-hy-

droxytryptamine 1A receptors,

958

�-endorphin antinociceptive systems,

biochemical and pharmacological

characterization, in rat, 65

inhibition of nociceptive dorsal horn

neurons, 5-HT3 receptors and, in

rats, 116

sites mediating cannabinoid-induced

antinociception, in rats, 585

Peripheral nervous system, opioid recep-

tors, effects in acute morphine

immunomoduhation, in rats, 626

Peris, J. : Repeated cocaine injections de-

crease the function of stniatal

y-aminobutynic acidA receptors,

1002

Perumattam, J. , see Endemann, G. , 5

Peter, C. P., Guy, J., Shea, M., Bagdon, W.,Kline, W. F. and Hayes, W. C.:Long-term safety of the ami-nobisphosphonate ahendronate in

adult dogs. I. General safety and

biomechanical properties of bone,271

Peter, C. P., see Balena, R., 277Peterson, P. D., see Haynes, J., Jr., 752Phenylephrine, ontogenic differences in

function, myocardium, rat, 1155

7-(2-Phenylethyl)-5-amino-2-(2-furyh)-

pyrazolo-[4,3-e]- 1 ,2,4-tria-

zolo[i,5-c]pyrimidine, see SCH

58261

Phosphodiesterase, inhibition by EHNA,

and hypoxic pulmonary vasocon-striction reversal, in rat lung, 752

Phosphodiesterase 4, isozymes in human

monocytes, 810

Phosphodiester DNA, 9SmTc�labeled, invitro and in mice, 326

Phosphoidesterase, inhibitor rohipram,

stimulation of renin secretion,

1073

Phosphohipase A2, mechanisms, involve-

ment in development of stimulantsensitization, 1244

Phosphohipase D, activation via A3 recep-

tors, in rat mast cells, 837

Phosphorothioate DNA, BBmTc�labeled, invitro and in mice, 326

Phosphorothioate oligodeoxynucleotides,

[3H1-biotinylated, pharmacoki-netics and blood-brain barrier

transport, 206

Physical dependence

acute opioid, dexamethasone effects on,

743

buprenorphine, in humans, 449

Piattoni-Kaphan, M., see Gopalakrishnan,M., 289

Pieretti, S., see Capasso, A., 743

Pigment, arbutin effects, in human meha-nocytes, 765

Pi#{241}eyro, G. and Blier, P.: Regulation of5-hydroxytryptamine releasefrom rat midbrain raphe nuclei by

5-hydroxytryptamine receptors:Effect of tetrodotoxin, G proteininactivation and long-term anti-depressant administration, 697

Pintor, J., see King, B. F., 93

Piperidine, repeated administration, loco-

motor activity and, C57BL/6

mice, 904

Placenta, term, cimetidine uptake intosyncytial microvillus membrane

vesicles, in human, 219

Platelets, L-arginine-mtric oxide pathway,

L-arginine analog effects on, in

human, 253Phebani, M., see Glavin, G. B., 1174Poet, T. S., see Kraner, J. C., 258Polavarapu, R., see Thompson, T. A., 1201Porat, 0., Neumann, D. Zamir, 0., Nachs-

hon, S., Feign, E., Cohen, J. and

Zamir, M.: Erythropoietin stimu-hates atrial natriuretic peptide se-

cretion from adult rat cardiacatrium, 1162

Positron emission tomography, vigaba-

tnin, modulation of benzodiaz-

epine receptor activity, baboon,977

Potassium channels, VIP effects on, medi-

ation by G protein, 690

Potassium current, ventricular and sino-

atrial node cells, dual actions ofnovel class III antiarrhythmic

drug NE-10064, 1149

Powell, W. S., Rokach, J., Khanapure, S.P., Manna, S., Hashefi, M., Gray-eh,S., Macleod, R. J., Falck, J. R.

and Bhatt, R. K.: Effects of me-

tabohites of leukotriene B4 on hu-

man neutrophil migration and cy-tosohic calcium levels, 728

Powers, A., see Fan, N. Y.-T., 875

Poyser, R. H., see Bril, A., 637

Pradier, L.., see Sagan, S., 1039

Prazosin, antipunishment effects, in pi-geon, 388

Pregnant myometrium, inositol phosphate

generation, beta adrenergic re-ceptors and, in rat, 130

Primus, R. J., Yu, J., Xu, J., Hartnett, C.,

Meyyappan, M., Kostas, C., Ram-

abhadran, T. V. and Gallager, D.W.: Allosteric uncoupling afterchronic benzodiazepine exposureof recombinant -y-aminobutynic

acidA receptors expressed in Sf��cells: Ligand efficacy and subtype

selectivity, 882Prinssen, E. P. M., Kleven, M. S., Vignon,

J., Kamenka, J.-M. and Koek,

Effects of repeated administra-tion of N-[i-(2-benzo(b)-thiophe-

nyl)cyclohexyhlpiperidine and co-

caine on locomotor activity inC57BL/6 mice, 904

Pritchard, G. A., see von Mohtke, L. L., 370

Proksch, J. W., Traylor, L. A. and Mayeux,

P. R.: Effects ofhipid A on calciumhomeostasis in renal proximal tu-

bules, 555

Propionyl-L-cannitine, effects on motornerve conduction, autonomic car-diac function, and nerve bloodflow, vs aldose reductase inhibi-tor, in rats with diabetes, 49

Prostacychin, synthesis, muscarinic recep-ton involved in, rabbit heart, 934

Prostaglandins, direct cellular protection

by, gastric mucosal cells, 1174

Protein C, activated, infarct size in caninemodel of myocardial reperfusioninjury, 1104

Protein kinase C, activator, contractionsmediated by, resistance vessels,867

Proteins

Geffects on 5-HT1D receptors, in rat

midbrain raphe nuclei, 697mediation of VIP effects by, 690

serum, bupivacaine binding, human,

i09Pulmonary vasoconstriction, hypoxic, re-

versal by EHNA, in rat lung, 752Purinoceptors, Pi. folhicular oocyte, X. lae-

vis, 93Pyridonecarboxyhic acid, transport, LLC-

PKi cell line, 1143N-(29(4-(2-Pynimidinyl)-i-piperazinyh)eth-

yl)tricyclo(3.3.i.i(3,7)) decane-i-carboxamide, see WY 50,324

2 i-(4-(2,6-di- 1-Pyrrohidinyl-4-pynimidi-

nyh)-i-piperazinyl)-16 alpha-

1996 Index 1315methyl-pregna-i,4,9(1 1)-triene-

3,20-dione, see U74006F

Quirion, R., see Bouchard, P., 223

Raasch, W., see Regunathan, S., 1272

Raffa, R. B., Schupsky, J. J. and Jacoby, H.

I.: Endothehin-induced nocicep-tion in mice: Mediation by ETA

and ETB receptors, 647Raftogianis, R. B., Franklin, M. R. and

Galinsky, R. E.: Effect of lipid-

free total parenteral nutrition onhepatic drug conjugation in rats,602

Ramabhadran, T. V., see Primus, R. J., 882Ramanathan, V. K., see Chung, S.-J., 676Ramwelh, P. W., see Farhat, M. Y., 652

Raphe nuclei, 5-HT1D receptors, regula-tion of, in rat midbrain, 697

Reactive oxygen species, cell injury and,cytoprotective actions of haz-aroids, 1224

Receptorsacetylchohine, presynaptic control of do-

pamine release by, in rat stria-

tum synaptosomes, 616adenosine, ‘25I-APE binding, in coro-

nary artery, 284adenosine A1 antagonist WRC-0571,

characterization, 490adenosine A2a, antagonist SCH 58261,

pharmacological profile, 398adenosine A3 phospholipase D activa-

tion via, in rat mast cells, 837angiotensin II, antagonists, urate trans-

porter interactions, in rat renal

brush-border membranes, 125cannabinoid CBi, immune activation

and, 776dopamine: see Dopamine receptorsendothehin, antagonist SB 217242, phar-

macological characterization, 609endothelinA

antagonist A-127722, pharmacohogi-cal characterization, 473

nociception mediation by, in mice, 647endothehinB nociception mediation by,

in mice, 647glutamate

metabotnopic higands, modulation ofseizures by, in mice, 5i6

NMDA, subunits, striatal motor regu-lation by, 342

5-HT1A, agonist/5-HT2�2� antagonistanxiohytic antipunishment ef-fects, in pigeon, 388

5-HT1D, regulation in rat midbrain na-phe nuclei, 697

5-HT2�2�, antagonisti5-HT1� agonistanxiolytic antipunishment ef-fects, in pigeon, 388

5-HT2B, pharmacologic characteriza-tion, 720

5-HT3, and periaqueductal gray-inducedinhibition of nociceptive dorsalhorn neurons, in rats, 1 i6

imidazohine, and cardiovascular effectsof moxonidine, nilmenidine and

chonidine, in rabbits, 411muscarinic

4-DAMP analog binding, 405tetrahydro-9-aminoacnidine effects

on, in rat hocus ceruleus neurons,

137

neurokinin 1, intrathecal antagonist ef-

fects on electrocorticographic de-synchronization, in rats, 2i2

neurokinin 2, intrathecal antagonist ef-

fects on ehectrocorticographic de-synchronization, in rats, 212

nicotinic acetyhchohinea4132, expression, pharmacologic prop-

erties and regulation, 289agonist epibatidine, effects on neuro-

transmitter release, in rats, 509

neural effects in medial septum, 482

reduction by nereistoxin, whole chickcihiary ganghion studies, 169

NMDAglutamate, subunits, striatal motor

regulation by, 342in NT2-N neurons, characterization,

819

presynaptic control of dopamine re-lease by, in rat striatum synapto-somes, 616

remacemide and des-glycine metabo-hite blockade, 161

opioid

delta, spinal, analgesic potency, in

amphibians, 440effects in acute morphine immuno-

modulation, in rats, 626kappa

spinal, analgesic potency, in am-phibians, 440

supraspinal, antinociceptive effects,

801

mu, spinal, analgesic potency, in am-phibians, 440

tetrahydro-9-aminoacridine effectson, in rat locus ceruleus neurons,137

purinergic, P1, folhicular oocyte, X. lae-vis, 93

sigma, in vivo labeling, modulation byNPY and CGRP, in mouse brain,223

thromboxane A2 desensitization, ini321N human astrocytoma cells,829

Regunathan, S., Youngson, C. , Raasch,W., Wang, H. and Reis, D. J.: Imi-dazohine receptors and agmatinein blood vessels: A novel system

inhibiting vascular smooth mus-cle proliferation, 1272

Reid, I. A., see Chiu, N., 1073Reid, M. S., Hsu, K., Tolliver, B. K., Craw-

ford, C. A. and Berger, S. P.: Ev-idence for the involvement ofphosphohipase A2 mechanisms inthe development of stimulantsensitization, 1244

Reis, D. J., see Regunathan, S., 1272Reisine, T., see Liapakis, G., 1089

Remacemide

des-glycine metabohite, NMDA receptor

blockade by, 161NMDA receptor blockade by, 161

Renal tubulesdistal, cellular ATP depletion by iodoac-

etate and cyanide, 194proximal, calcium homeostasis in, lipid

A effects on, 555Rengasamy, A. and Johns, R. A.: Determi-

nation of Kmfor oxygen of nitric

oxide synthase isoforms, 30

Renin, secretion, stimulation by phos-

phodiesterase IV inhibitor rolip-

ram, 1073Repenfusion injury, myocardial, activated

protein C effects on infarct size,canine model, 1104

Reverse transcriptase, inhibitor UC 38,anti-HIV effects, 298

Rhoden, K. J., Tahhini, G. and Douglas, J.

S.: H�-K� ATPase inhibitors

cause relaxation of guinea pig

and human airway smooth mus-

cle in vitro, 897Richard, J., see Lew, R., 855Richards, J. B., see Sabol, K. E., 846

Rilmenidine, cardiovascular effects, imi-dazoline receptor interactions, inrabbits, 411

Ring, B. J., Cathow, J., Lindsay, T. J.,Gillespie, T., Roskos, L. K., Cer-

imehe, B. J., Swanson, S. P., Ham-mon, M. A. and Wrighton, S. A.:

Identification of the human cyto-

chromes P450 responsible for the

in vitro formation ofthe major ox-

idative metabohites of the anti-psychotic agent olanzapine, 658

Ritanserin, antipunishment effects, in pi-

geon, 388Rivier, J., see Liapakis, G., 1089Rivier, J., see Rodriguez de Fonseca, F., 56

Rodan, G. A., see Balena, R., 277Rodriguez de Fonseca, F., Rubio, P., Men-

zaghi, F., Merlo-Pich, E., Rivier,J., Koob, G. F. and Navarro, M.:Corticotropin-releasing factor

(CRF) antagonist[D-Phe12,Nle2�38,C”MeLeu37]CRF

attenuates the acute actions of

the highly potent cannabinoid re-ceptor agonist HU-210 on defen-sive-withdrawal behavior in rats,56

Rogawski, M. A., see Hough, C. J., 143Rogawski, M. A. , see Subramaniam, S.,

161Rogers, W. L., see Seymour, A. A., 708Rokach, J., see Powell, W. S., 728Rohipram, phosphodiesterase IV inhibitor,

stimulation of renin secretion,

1073

Roll, K., see Ujhehyi, M. R., 683

Roman, F., see Bouchard, P., 223Rosebrough, S. F. and Hashmi, M.: Galac-

tose-modified streptavidin-GC4antifibrin monoclonal antibodyconjugates: Application for two-step thrombus/embohus imaging,

770Rosen, M. I., McMahon, T. J., Hameedi, F.

A., Pearsahh, H. R., Woods, S. W.,Kreek, M. J. and Kosten, T. R.:Effect of chonidine pretreatment

on naloxone-precipitated opiate

withdrawal, 1128Rosenzweig-Lipson, S., see Bergman, J.,

942

Roskos, L. K., see Ring, B. J., 658Rossoni, G., Sala, A., Berti, F., Testa, T.,

Buccelhati, C., Molta, C., Muller-Peddinghaus, R., Maclouf, J. andFohco, G. C.: Myocardial protec-tion by the heukotriene synthesisinhibitor BAY X1005: Importance

1316 Index Vol. 276

of transcellular biosynthesis of

cysteinyl-leukotrienes, 335

Roxindole, psychopharmacological profile,41

Ruan, Y., see Kan, H., 934

Rubin, C. S., see Widnell, K. L., 306

Rubio, P., see Rodriguez de Fonseca, F., 56Rudolf, G. D., see Standaert, D. G., 342Ruffolo, R. R., Jr., see Bril, A., 637

Rusckowski, M., see Hnatowich, D. J., 326Russeh, F. G. M., see An, E. M. van der, 219

Russell, D. S., see Widnell, K. L., 306Russell, J. D., see McMahon, J. B., 298Rutaecarpine, vasorehaxing action, vascu-

lar smooth muscle and endothe-

hal cell calcium concentration,

1016Sabol, K. E., Low, R., Richards, J. B., Vos-

men, G.L. and Seiden, L. S.: Meth-

ylenedioxymethamphetamine-

induced serotonin deficits are

followed by partial recovery overa 52-week period. Part 1: Synap-tosomal uptake and tissue con-

centrations, 846

Sabol, K. E., see Low, R., 855Sacaan, A. I., Menzaghi, F., Dunlop, J. L.,

Correa, L. D., Whelan, K. T. andLloyd, G. K.: Epibatidine: A nico-tinic acetylchohine receptor ago-nist releases monoaminergic neu-

rotransmitters: In vitro and in

vivo evidence in rats, 509

Sadowski, B., see Mogil, J. S., 532Sagan, S., Chassaing, G., Praidier, L. and

Lavielle, S.: Tachykinin peptidesaffect differently the second mes-senger pathways after binding to

CHO-expressed human NK-1 re-ceptors, 1039

Sagratella, S., see Capasso, A., 743

Saita, K., Ohi, T., Hanaoka, Y., Furukawa,S., Furukawa, Y., Hayashi, K.and Matsukura, S.: A catechol de-

rivative (4-methylcatechol) acceh-

erates the recovery from experi-

mental acrylamide-induced

neuropathy, 231Saito, H., see Ohtomo, T., 1143Sakai, K., Nakahata, N. , Ono, H.,

Yamamoto, T. and Ohizumi, Y.:Homologous desensitization ofthromboxane A2 receptor ini32iNi human astrocytoma

cells, 829Sakakibara, F., see Hotta, N., 49Sakamoto, N., see Hotta, N., 49Sakamoto, S. , see Shimizu-Sasamata, M.,

84

Sakiyama, H., see Matsuyama, S., 989

Saha, A., see Rossoni, G., 335Samii, K., see Mazoit, J. X., 109Sanguinetti, M. C., see Sudo, G. Z., 951

Sannajust, F., see Chan, C. K. S., 41iSano, T., see Hnatowich, D. J., 326Sarwinski, S., see Lee, T. J.-F., 353SB 217242, pharmacological characteriza-

tion, 609

SCH 58261, pharmacological profile, 398Schecter, R. L., see Wang, T., 1169Schlicker, E., see Leurs, R., 1009Schmid, L., Bottlaender, M., Brouillet, D.,

Fuseau, C. and Maziere, M. : Vi-

gabatnin modulates benzodiaz-epine receptor activity in vitro: A

positron emission tomographystudy in baboon, 977

Schultz, R. J., see McMahon, J. B., 298Schupsky, J. J., see Raffa, R. B., 647Schur, M., see Ujhelyi, M. R., 683Schwinger, R. H. G., M#{252}hler-Ehmsen, J.,

BOhm, M. and Erdmann, E.: En-antioselective inotropic actions ofthe Nat-channel activators BDF9i48, BDF 9196 and BDF 9167 inhuman failing and nonfaihingmyocardium, 1180

Seedor, J. G., see Balena, R., 277Seiden, L. S., see Low, R., 855Seiden, L. S., see Sabol, K. E., 846Seizures, modulation by metabotropic glu-

tamate receptor ligands, in mice,516

Seki, J., see Kita, Y., 421Sekioka, K, see Abe, Y., 433Self, D. W., see Widnell, K L., 306Sensitivity, morphine, nociceptive assay

and, in genetic models, 532Sensitization, cocaine, K-opioid agonist ef-

fects on, 545Serotonin, see 5-Hydroxytryptamine

Serum proteins, bupivacaine binding, hu-man, 109

Settembrini, B. P., see De Gennaro Col-onna, V., 795

Severs, W. B., see Thompson, T. A., 1201Seymour, A. A., Asaad, M. M., Abboa-

Offei, B. E., Smith, P. L., Rogers,W. L. and Dorso, C. R.: Determi-nants of in vivo activity of neutralendopeptidase 3.4.24.11 and an-giotensin converting enzyme in-hibitors, 708

Shader, R. I., see von Moltke, L. L., 370Shahinfar, S., see Hatch, M., 187

Sham, W., see Davis-Cox, M. I., 758Shan, J., see Wang, G.-J., 1016Shen, D. D., see Adkison, K. D. K., 1189Shetty, S. S., see Chin, M. H., 74

Shimizu-Sasamata, M., Kawasaki-Yat-sugi, S., Okada, M., Sakamoto, S.,

Yatsugi, S.-I., Togami, J., Ha-tanaka, K-I., Ohmoni, J., Ko-shiya, K., Usuda, S. and Murase,

K. : YM9OK: Pharmacologicalcharacterization as a selectiveand potent a-amino-3-hydroxy-5-methyhisoxazole-4-propionate/kainate receptor antagonist, 84

Shiosaki, K., Jenner, P., Asin, K. E., Brit-ton, D. R. , Lin, C. W.,Michaelides, M., Smith, L., Bian-chi, B., Didomenico, S., Hodges,L., Hong, Y., Mahan, L., Mikusa,J., Miller, T., Nikkel, A., Stashko,M., Witte, D. and Williams, M.:ABT-431: The diacetyl prodrug of

A-86929, a potent and selectivedopamine D1 receptor agonist: Invitro characterization and effectsin animal models of Parkinson’sdisease, 150

Shippenberg, T. S., LeFevour, A. and Hei-dbreder, Ch.: K-Opioid receptoragonists prevent sensitization tothe conditioned rewarding effectsof cocaine, 545

Shoemaker, R. H., see McMahon, J. B., 298Sidhu, J. S. and Omiecinski, C. J.: Forsko-

lin-mediated induction of

CYP3A1 mRNA expression in pri-many rat hepatocytes is indepen-dent of elevated intracellular cy-chic AMP, 238

Sigma receptors, in vivo labeling, modula-tion by NPY and CGRP, in mouse

brain, 223Sills, M. A., see Chin, M. H., 74Simms, D. and Gallagher, J. P.: Modifica-

tion of serotonin responses in rat

dorsolaterah septal nucleus neu-

rons by acute and chronic cocaine,1292

Simon, R. P., see Graham, S. H., 1

Simpson, P. J., see Hahn, R. A., 1104Sleep, non-REM b, MK-801 effects on, 737Smit, H., see Mosehey, R. H., 561Smith, C. L., see Hnatowich, D. J., 326Smith, D. J., see Monroe, P. J., 65Smith, D. L., see Monroe, P. J., 65Smith, L., see Shiosaki, K., 150Smith, P., see Obistein, E. H., 609

Smith, P. L., see Seymour, A. A., 708Smooth muscle

airway, relaxation, H�-K� ATPase in-

hibitors and, guinea pig, 897colonic, relaxation by somatostatin, in

rabbit, 714

tracheal, chloride current, acetylcho-line-induced oscillations, in swinecells, 178

vascularcalcium dependence of indohactam-

mediated contractions, 867

imidazohine receptors and agmatinein blood vessels, 1272

Smooth muscle cells, vascularcAMP in, estradioh effects on, in rat

lung, 652

intracellular calcium concentration, ru-taecarpine effects, 1016

Sodium channel activators, enantioselec-tive inotropic actions of, humanmyocardium, 1180

Somatostatincolon relaxation by, in rabbit, 714effects on membrane potential and input

resistance of ventral subicularneurons, in rat, 426

stimulation, canine stomach, pentagas-

tric-stimuhated histamine releaseand, 984

Somatostatin receptors, subtype SSTR1,

development of a selective ago-nist, 1089

Song, J., see Miriel, V., 867Sorrentino, L., see Capasso, A., 743Spealman, R. D., see Bergman, J., 942Spodoptera frugiperda, D2 dopamine re-

ceptor coupling in, 784SSTR1, somatostatin receptor subtype, de-

vehopment of a selective agonist,1089

Stack, E. J., see Edwards, R. M., 125Standaert, D. G., Testa, C. M., Rudolf, G.

D. and Hohhingsworth, Z. R.: Inhi-bition of N-methyl-D-aspartateglutamate receptor subunit ex-pression by antisense ohigonucle-otides reveals their role in stria-tal motor regulation, 342

Stanulis, E. D., see Jeong, T. C., 1257Stark, C., see Bahena, R., 277Staruch, M. J., see Dumont, F. J., 1078Stashko, N., see Shiosaki, K., iSO

1996 Index 1317

Steir, C. T., Jr., see Fan, N. Y.-T., 875

Steroids, transport, organic anion trans-

porter of mammalian liver, 891

Stevens, C. W. : Relative analgesic potency

of mu, delta and kappa opioids

after spinal administration in

amphibians, 440

Stewart, J., see Ujhelyi, M. R., 683

Stinson, S. F., see McMahon, J. B., 298

Stitzer, M. L., see Eissenberg, T., 449

Streptavidin-GC4 antifibnin monoclonalantibody conjugates, galactose-

modified, two-step thrombus/

embolus imaging application, 770

Striatum

dopamine D1 receptor effects, receptordesensitization, studies with

A-77636, 1022

GABA receptors, effects of repeated co-

caine injections, 1002Subiculum, ventral neurons, somatostatin

effects on membrane potential

and input resistance, in rat, 426

Subramaniam, S. , Donevan, S. D., and Ro-gawski, M. A.: Block of the N-methyl-D-aspartate receptor by

remacemide and its des-glycinemetabohite, 161

Substance P, human NK-i receptors,

tachykinin peptide effects, CHO

cells, 1039

Sudo, G. Z. and Sanguinetti, M. C.: Intra-

cellular [Mg� ‘idetermines speci-ficity of K� channel block by aclass III antiarrhythmic drug,

951Sugihara, H., see Yamada, K., 460Sulfation, total parenteral nutrition ef-

fects on, in rats, 602

Sulfhydryls, direct cellular protection by,

gastric mucosal cells, ii74

Sullivan, J. P., see Gopalakrishnan, M.,289

Sun, F. F., see Taylor, B. M., 1224Sun, F. F., see Yue, G., 265Swanson, S. P., see Ring, B. J., 658Synaptosomes

dopamine release, presynaptic controlby cholinergic and NMDA recep-

tons, in rat striatum, 616

MDMA-induced serotonin deficit up-take, 846

Syncytiah microvillus membrane vesicles,

cimetidine uptake into, in humanterm placenta, 219

Szabo, S., see Glavin, G. B., 1174Szarowski, D., see Davis-Cox, M. I., 758Sze, P. Y.: Glucocorticoid interactions with

ethanol effects on synaptic

plasma membranes: Influence on

[1251]calmoduhin binding, 578

T2, IL-2 transcription suppression by, 316Tachykinin peptides, modulation of hu-

man NK-i receptors, CHO cells,

1039

Tachykinins, intrathecal, effects on elec-

trocorticographic desynchroniza-tion, in rats, 212

Tachyphylaxis, to angiotensin II, in rat

mesenteny in vivo, 13Tacrine, see Tetrahydro-9-aminoacridineTakamatsu, H., see Kita, Y., 421Tahlini, G., see Rhoden, K J., 897Tanaka, C., see Matsuyama, S., 989

Tao, X., Davis, L. S., Hashimoto, K. andLipsky, P. E.: The Chinese herbal

remedy, T2, inhibits mitogen-induced cytokine gene transcrip-tion by T cells, but not initial sig-

nal transduction, 316

Tassaneeyakul, W., Birkett, D. J., Ed-

wards, J. W., Veronese, M. E.,Tassaneeyakul, W., Tukey, R. H.and Miners, J. 0. : Human cyto-chrome P450 isoform specificityin the regiosehective metabolism

of toluene and o-, m- and p-xyhene, 101

Tassaneeyakul, W. , see Tassaneeyakul,

W., 101Taurine, saturable cerebrospinal fluid dis-

position, in rat, 676

Taylor, B. M., Fleming, W. E., Benjamin,C. W., Wu, Y., Mathews, W. R.and Sun, F. F. : The mechanism of

cytoprotective action of lazaroids

I: Inhibition of reactive oxygenspecies formation and lethal cell

injury during periods of energydepletion, 1224

Technetium-99m, -labeled phosphodiesterDNA vs phosphorothioate DNA,

in vitro and in mice, 326

Teraoka, K., see Morita, K., 996Tesson, F., Limon, I., Gargahidis-Mouda-

nos, C. and Parini, A. : I2-Imidazo-

line binding sites: Relationship

with different monoamine oxi-dase domains and identification

ofhistidine residues mediating li-

gand binding regulation by W’,

359Testa, C. M., see Standaert, D. G., 342Testa, T., see Rossoni, G., 335Tetrahydro-9-aminoacridine, effects on

muscarinic and opioid currents,in rat locus ceruleus neurons, 137

Tetrodotoxin, effects on 5-HT1D receptors,in rat midbrain raphe nuclei, 697

Theophylhine, metabolism, human liver

microsomes, 912

Thom, S. R., see Chen, Q., 929Thompson, T. A., Lewis, J. B., Dejneka, N.

S. , Severs, W. B., Polavarapu, R.

and Bilhingsley, M. L.: Induction

of apoptosis by organotin com-

pounds in vitro: Neuronal protec-

tion with antisense ohigonucleo-

tides directed against stannin,

1201

Thompson, W. J., see Haynes, J., Jr., 752Thomsen, C., see Dalby, N. 0., 516

Thornton-Manning, J., Appleton, M. L.,Gonzalez, F. J. and Yost, G. S.:Metabolism of 3-methylindole byvaccinia-expressed P450 en-

zymes: Correlation of 3-methyl-eneindolenine formation and pro-

tein-binding, 21

Thrombosis, factor Xa, DX 9065A inhibi-

tion of, 1030Thromboxane A2 receptors, desensitiza-

tion, in i321N human astrocy-

toma cells, 829Thrombus/embolus imaging, two-step, ga-

lactose-modified streptavidin-

GC4 MAb conjugates for, 770

Timmenman, H., see Leurs, R. , 1009

Tirilazad mesylates, 21-aminosteroid, IBDamelioration by, in rats, 265

Tjia, J. F., Colbert, J. and Back, D. J.:

Theophylhine metabolism in hu-

man liver microsomes: Inhibition

studies, 912

TKS159, effects on gastric motility and

acetyhchohine release, guinea pigstomach, 989

T lymphocytes

activation, and CB1 cannabinoid recep-

tors, 776

IL-2 transcription, suppression by T2,

316Tofovic, S. P. and Jackson, E. K.: Tachy-

phyhaxis to angiotensin II and[Phe4]-angiotensin II in the rat

mesentery in vivo, 13

Togami, J., see Shimizu-Sasamata, M., 84

Tokarz, J. J., see Lash, L. H., 194

Tolerance, see also Dependencechronic ethanol, reversal by cAMP-

dependent protein kinase, 365Tolliver, B. K., see Reid, M. S., 1244Tohuene, cytochrome P450 isoform metab-

ohism, human, 101

Torphy, T. J., see Manning, C. D., 810

Total parenteral nutrition, effects on he-

patic drug conjugation, in rats,

602Tracheal smooth muscle

chloride current, acetylcholine-inducedoscillations, in swine cells, 178

H�-K� ATPase inhibitors and, humanand guinea pig, 897

Traylor, L. A., see Proksch, J. W., 555Triazoham, biotransformation by liver mi-

crosomes in vitro, human, 370

Tributylmethyhammonium, hepatic up-

take and bihiary excretion, ratliver plasma membrane vesiclestudies, 561

Tributyltin, selective toxicity of, induction

of apoptosis by organotin com-

pounds, 1201

Triethyltin, selective toxicity of, induction

of apoptosis by organotin corn-

pounds, i2Oi

TrifunoviC, R. D. and Brodie, M. S.: Theeffects ofchomipramine on the ex-

citatory action of ethanol on do-paminergic neurons ofthe ventraltegmental area in vitro, 34

Trimethyltin, selective toxicity of, induc-

tion of apoptosis by organotin

compounds, 1201

Tripterygium wilfordii Hook F, T2 extract,

suppression of IL-2 transcription

by, 316

Trizna, W., see Edwards, R. M., 125Tukey, R. H., see Tassaneeyakul, W., 101

Tumor necrosis factor, production, modu-

lation by methylxanthines and,

mouse liver, 968

Turner, J. N., see Davis-Cox, M. I., 758

UC 38, anti-HP! effects, 298U74006F, IBD amelioration by, in rats,

265US0,488H, antinociception induced by,

cromakahirn effects, 1136

Ujhelyi, M. R., Bottorif, M. B., Schur, M.,

Roll, K., Zhang, H., Stewart, J.,

and Markel, M. L.: Urine acidifi-

cation affects the activity of the

1318 Index Vol. 276

organic base transporter in a non-

stereoselective manner, 683

Uratehomeostasis, hosartan effects on, 187

transport

intestinal, losartan effects on, 187

renal brush-border membrane, All

antagonist interactions, in rat,

125

Urine, acidification, enhancement of or-

ganic cation secretion by, 683

Usuda, S., see Shimizu-Sasamata, M., 84

Vagus stimulation, E-4031 effects on, in

dogs, 467

Vaidya, V. A., see Widnell, K. L., 306

Valproic acid, uptake, rat brain, medium-

chain fatty acid transporter medi-

ation of, ii89

VanBoom, J. H. , see Ouwerkerk-Ma-hadevan, S., 923

Van Solkema, B. G. H., see Moseley, R. H.,

561Vargas, R., see Farhat, M. Y., 652

Varma, D. R., see Deng, X. F., 1155

Vascular smooth muscle cells, cAMP in,

estradiol effects on, in rat hung,

652Vasoactive intestinal peptide, effects on

K� channels, mediation by G pro-tein, 690

Vasoconstriction, hypoxic pulmonary, re-

versal by EHNA, in rat hung, 752

Vasodilation, cerebral neurogenic, inhibi-

tion by L-glutamine and NOS, 353

Vasopressin, antidiuretic response to lan-

reotide and, diabetic rat, 875Vaziri, N. D., see Hatch, M., 187Ventral tegmental area, dopaminergic

neurons, ethanol-induced excite-

tion of, effects of clomipramine

on, in vitro, 34

Ventricular arrhythmia, BRL-32872 anti-

arrhythmic profile, 637

Ventricular myocytes

potassium channel block by class II an-

tiarrhythmic drug, intracellular

magnesium effects, 951subtypes of muscarinic receptors in,

prostacychin synthesis, rabbit

heart, 934

Veronese, M. E. , see Tassaneeyakuh, W.,

101

Verrijt, C. E. H., see Aa, E. M. van der, 219Vertebrae, L5, histomorphometric analy-

sis, with long-term alendronate,in adult dogs, 277

Vigabatrin, modulation of benzodiazepinereceptor activity, positron emis-

sion tomography study, baboon,

977

Vignon, J., see Prinssen, E. P. M., 904

VIP, see Vasoactive intestinal peptide

Vistica, D. T., see McMahon, J. B., 298

Vollinga, R. C., see Leurs, R., 1009

Von Geldern, T. W., see Opgenorth, T. J.,

473

von Moltke, L. L., Greenbhatt, D. J., Har-

matz, J. S., Duan, S. X., Harrel, L.

M., Cotreau-Bibbo, M. M., Prit-

chard, G. A., Wright, C. E. and

Shader, R. I.: Triazolam biotrans-

formation by human liver micro-

somes in vitro: Effects of meta-

bohic inhibitors and clinical

confirmation of a predicted inter-

action with ketoconazole, 370Vosmer, G. L., see Lew, R., 855Vosmer, G.L., see Sabol, K. E., 846

Wainscott, D. B., Kursar, J. D., Baez, M.

and Nelson, D. L. : Pharmacologic

characterization of the human

5-hydroxytryptamine25 receptor:Evidence for species differences,

720

Wakao, T., see Hotta, N., 49

Wang, G.-J., Shan, J., Pang, P. K. T.,

Yang, M. C. M., Chou, C.-J. andChen, C-F. : The vasorelaxing ac-tion of rutaecarpine: Direct para-

doxical effects on intracellularcalcium concentration of vascularsmooth muscle and endothehial

cells, 1016

Wang, H., see Regunathan, S., 1272

Wang, S., see King, B. F., 93Wang, T., Chen, X., Schecter, R. L., Ba-

rucheh, S., Ahaoui-Jamahi, M.,

Melnychuk, D. and Batist, G.:Modulation of glutathione by acysteine pro-drug enhances in

vivo tumor response, 1169

Wang, W., see Moseley, R. H., 561

Wang, Y.-H., see Munir, M., 819Weinstock, J., see Edwards, R. M., 125Wendel, A., see Leist, M., 968Wessale, J. L., see Opgenorth, T. J., 473Whelan, K T., see Sacaan, A. I., 509Whigan, D. B., see Grover, G. J., 380Widnell, K. L., Self, D. W., Lane, S. B.,

Russell, D. S., Vaidya, V. A.,Miserendino, M. J. D., Rubin, C.S., Duman, R. S. and Nestler, E.J.: Regulation of CREB expres-sion: In vivo evidence for a func-tional role in morphine action in

the nucleus accumbens, 306Wiederrecht, G., see Dumont, F. J., 1078Willer, J.-C., see Bustamante, D., 1232

Williams, M., see Shiosaki, K., 150

Williams, S. A., see Abbruscato, T. J., 1049

Willis, W. D., see Lin, Q., 958

Willis, W. D., see Peng, Y. B., 116Winn, M., see Opgenorth, T. J., 473Winnard, P., Jr., see Hnatowich, D. J., 326Winsauer, P. J., Bixler, M. A. and Mehe, P.

C.: Comparison of the effects oftypical and atypical anxiolytics

on learning in monkeys and rats,

liii

Withdrawalacute HU-2i0 effects on, mediation by

corticotropin-releasing factor, in

rats, 56

acute opioid, dexamethasone effects on,743

buprenorphine, antagonist-precipitated,

in humans, 449

Witte, D., see Shiosaki, K., 150

Wolfe, B. B., see Mumr, M., 819Wong, P. Y.-K., see Yue, G., 265Woods, E. B., see Lash, L. H., 194

Woods, S. W., see Rosen, M. I., 1128Wouterse, A. C., see An, E. M. van der, 219

WRC-057i, characterization, 490Wright, C. E., see von Moltke, L. L., 370

Wrighton, S. A., see Ring, B. J., 658

Wu, D., Boado, R. J. and Pardridge, W. M.:Pharmacokinetics and blood-brain barrier transport of [3H]-

biotinylated phosphorothioate oh-

godeoxynucheotide conjugated toa vector-mediated drug deliverysystem, 206

Wu, P. H., Liu, J.-F., Wu, W. L., Lan#{231}a,A.J. and Kalant, H.: Development ofalcohol tolerance in the rat after a

single exposure to combined

treatment with arginine8-vaso-

pressin and ethanol, 1283

Wu, W. L., see Wu, P. H., 1283

Wu. Y., see Taylor, B. M., 1224

Wu-Wong, J. R., see Opgenorth, T. J., 473WY 50,324, antipunishment effects, in pi-

geon, 388

Wysocki, R. J., Jr., see Martin, P. L., 490

Xenopus laevis, follicular oocyte P1 purino-ceptors, 93

Xie, Y., McHugh, T., McKay, J., Jones, G.S., Jr. and Loring, R. H.: Evidence

that a nereistoxin metabolite, and

not nereistoxin itself, reduces

neuronal nicotinic receptors:Studies in the whole chick cihiary

ganghion, on isolated neurons andimmunoprecipitated receptors,169

Xing, P. L., see Glavin, G. B., 1174

Xu, J., see Pnimus, R. J., 882Xyhene, cytochrome P450 isoform metabo-

hism, human, 101

Yamada, K, see Ahi, H., 837Yamada, K., Noda, Y., Hasegawa, T.,

Komori, Y., Nikai, T., Sugihara,H. and Nabeshima, T.: The role ofnitric oxide in dizocilpine-induced

impairment of spontaneous alter-nation behavior in mice, 460

Yamamoto, T., see Sakai, K., 829

Yang, M. C. M., see Wang, G.-J., i016Yang, X., Criswell, H. E. and Breese, G. R.:

Nicotine-induced inhibition inmedial septum involves activa-

tion of presynaptic nicotinic cho-

hinergic receptors on y-aminobu-tynic acid-containing neurons,

482Yasuhara, M., see Ohtomo, T., 1143Yatsugi, S-I., see Shimizu-Sasamata, M.,

84

Yin, K., see Yue, G., 265YM9OK, pharmacological characteniza-

tion, 84

Yoo, S. D., Holladay, J. W., Fincher, T. K.,Baumann, H. and Dewey, M. J.:Altered disposition and antide-

pressant activity of imipraminein transgenic mice with elevated

alpha-i-acid glycoprotein, 918Yost, G. S., see Thornton-Manning, J., 21Young, R. and Glennon, R. A.: A three-

layer operant procedure differen-

tiates the stimulus effects of R(-)-MDA from S(+)-MDA, 594

Youngson, C., see Regunathan, S., 1272

Yu, J., see Primus, R. J., 882

Yue, G., Sun, F. F., Dunn, C., Yin, K andWong, P. Y.-K.: The 2i-aminos-teroid tirihazad mesylate canameliorate inflammatory bowel

disease in rats, 265

Zack, J. A., see Pardridge, W. M., 246Zamir, N., see Porat, 0., 1162

1996 Index 1319

Zamir, 0., see Porat, 0., 1162Zhang, H., see Ujhelyi, M. R., 683Ziganshin, A. U., see King, B. F., 93Ziganshina, L. E., see King, B. F., 93Zocchi, C., Ongini, E., Conti, A., Monopohi,

A., Negretti, A., Baraldi, P. G.

and Dionisotti, S.: The non-xan-thine heterocychic compound SCH58261 is a new potent and sehec-tive A2,, adenosine receptor an-tagonist, 398

Zohi, M., see De Gennano Colonna, V., 795Zou, H., see Mirieh, V., 867

.

I

;�‘:4, �

:td� � )iTS (i�

� �an contact Iqaku-S�o)c!dbe’ 31 19%

,‘.,,�1o

, . y � I � “

1�pany I

Williams & WilkinsA WAVERLY COMPANY

.- --- . � �----- -- I

���jIj I �i�I

I__ . � . r,ION

publishes experimetit�ir . �vit’ro andm t)j(70 systems that F�±� �gnificant and

original information on � .iolisrn and disposi-

tiOn of endogenous and exo� �us compounds, in-

cluding the metabolism of th �eutic agents and

environmental chemicals. The journal also iiwites

timely reviews, short communications and letters to

the Editor. All submissions are refereed to en�ore a

high standard of publication. The areas covered are:

. metabolism, metabolite identification and

mechanisms of metabolite formation

expression of drug metabolizing enzymes

regulation of drug metabolizing enzyme

gene expression

. toxicological consequences of xenobiotic

metabolism

. pharmacokinetics

I pl�i�nacodynamics

T his’�umal should be a standard reference in all

pharmacology and toxicology departments. It is

also a valuable resource for all medicinal chemists

invol�’ed in drug design and all hiochernists with

interest in dfllg metabolism, expression or drug

metabolizing enzymes and regulation of drug

metaholi:ing en:yme gene expression. Monthly

To order hy credit card, call TOLL-FREE

1 -800-638-642 3 in North America. Outside

North Americi, t�ix: 1-4 1 i.)- 36 l-8C�48 or call one

of our intern�itionaI othees: Tokyo (03) �689-54OO,

.� � I.()I’ILIOIl C�I 7 1- 3��-2�57. Flong Kong ?�52-2#{244}l0-2 3 39.

1. � .

� .$�

r�tl�Iv)

�� �

�j

S) -

�:

�p date .#{149}

�!�

COPYRIGHT © 1996 BY THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

MO

PHARUEditor: Raymond Dingledine, Ph.D.

Emory University School of Medicine

Atlanta, Georgia

Is your special interest receptors and

neurotransmitters...drug metabolism. ..antibic

and anticancer drug actions...or other areas

related to molecular basis of drug action? If �you should be subscribing to MOLECULAI

PHARMACOLOGY.

The editor’s and editorial board’s high

standards ensure that the papers you read in

MOLECULAR PHARMACOLOGY are on

the cutting edge of research on drug action and

selective toxicity at the molecular level.

Original applications of biochemistry,

biophysics, genetics, and molecular biology are

juxtaposed with innovative pharmacologic

research to elucidate basic problems inpharmacology and toxicology, including such

areas as molecular mechanisms involved in

drug receptor-effector coupling, xenobiotic

metabolism, and antibiotic and anti-cancer drug

action. Start your subscription today to ensure

access to the most newsworthy papers in your

field. Monthly

Cut out and send in the coupon or call

to start your subscription immediately,

1-800-638-6423 from anywhere in North

America. Outside North America, fax 1-410-

361-8048 or call one of our international

offices: Tokyo (03) 5689-5400, London 017 1-

385-2357, Hong Kong 852-2610-2339.

Williams & WilkinsA WAVERLY COMPANY

( YES! Enter my subscription.

�*... Avoid future rate increases and ensure uninterrupted

I service-enter your multiyear subscription today!

I MOLECULAR PHARMACOLOGY(monthly) I

� Individual: $1 15/yr Institution: $250/yr

I (Please add $35.00/yr. outside the U.S.; in Canada. also add 7% GST.)

I New Subscription Renewal II 3yrs 2yrs lyr I

I Name � � �----. �-�-----�-�--- --- - �- �- I

� Address �______________________________ -�- -- � -------�

I City/State/Zip ________--------� - II Payment Options: II Check enclosed (payable to Williams & Wilkins) II Bill me American Express II MasterCard VISA I

I Card # �- Exp. date II Signature or P.O. # ____________________ I

MD. ME. and IL subscnber�, must add state �aIes tax. Subscriptions outside the t1.S. rnu�t beprepaid in U.S. dollar’.. International order’.. fax xour order to -410-361-8048. In Japan.contact gaku.Shoin. MYW. Ltd. (03) �f�59.J4(5�j Rates valid through October 31. 996.

Dixcounts available to members on all ASPET puhlicationx. SAVE lO� when ordcrin� two.

I SAVE l5� when ordering three. SAVE 2O� when ordering all four puhltcations. II Williams & Wilkins II i�is. A Waverly Company II P.O. Box 23291

I Baltimore. MD 21203-9990

�M��±S PrIrnCdrnUSAS#{212}JO3OZJ

���ggy Jou rnalsPubilcatlons of the American Soclety for Pharmacology and Experlmental Therapeutics, Inc.

r

Return coupon to:Williams & Wilkins

A WAVERLY COMPANY

P.O. Box 23291. Baltimore. MD 2l203-999()I Pharmacological Reviews (quaiierI� I

I �1 Iit&li do ii S( i/x it �1 In tituti n ii S I I -i/x ir 1 In tr itnttt�. ‘S0/x ar I Add � � r dit .trd rd r all TOLL tREE I 50(1 615 64 � in \ )rth Amt.rw i

I 520/year for xuhscrtptioiix otttxide the [.S.: in Cattada. tl�.() .111(1 7� CJST. I Outside North America, fax 1-410-361-8048 or call one ot our international

I � Nc�� Subscription �1 Rciicx� :iI . offices: Tokyo (03) �$9.449) Londin Ol71.3$�2357, Hong Kong M�2.26l(I.2339Suh.crits, for: �1 3 �earx �1 2 �carx �1 I scar . S6J(O�/

[Jf�h4u

The Journal of Pharmacology and Experimental

Therapeutics

Editor: John A. Harvey. Ph.D.

JPET is respected the world over as one of the

leading research journals in the field of pharmacology. You’ll

find broad coverage of all aspects of the interactions of

chemicals with biological systems. including autonomic.

behavioral. cardiovascular. cellular. clinical. developmental.

gastrointestinal. in�iiiuno-. neuro-. pulmonary. and renal

phariiiacology. as well as analgesics. drug abuse. metabolism

atid disposition. cheniotherapy. and toxicology. i%’loiit/ilv.

Molecular Pharmacology

Editor: Raymond Dingledine. Ph.D.

The papers published in Molecular Pharmacology

are on the cutting edge of research on drug action and selective

toxicity at the molecular level. Original applications of

biochemistry. biophysics. genetics. and molecular biology are

juxtaposed with innovative pharmacologic research to elucidate

basic problems in pharmacology and toxicology. including such

areas as molecular mechanisms involved in drug receptor-

effector coupling. xenobiotic metabolism. and antibiotic and

anticancer drug action. Mouth/v

Drug Metabolism and Disposition: The Biological Fate

of Chemicals

Editor: Raymond F. Novak. Ph.D.

Drug Metabolism and Disposition publishes

experimental results from in vitlo and in t’ii’o systems that bring

VOL.1 signilicaiit and original information on metabolism and

disposition of endogenous and exogenous compounds. including

pharmacologic agelits and environmental chemicals. The areas

covered are: xenohiotic metabolism. expression of drug

metabolizing enzynies. regulation of drug metabolizing enzyme

gene expression. pharmacoki netics. pharmacodynamics and

toxicological consequences of xenohiotic nietabolism.

Mouth/v.

Pharmacological Reviews

Editor: David B. Bylund. Ph.D.

Pharmacological Reviews is a showcase forlniport�Lnt review articles in your field. featuring longer papers

Oil topics of high current interest. The areas covered in review

papers have included biochemical and cellular pharmacology.

drug nietaholisni and disposition. renal pharmacology.

neuropharmacology. hehav ioral pharmacology. clinical

pharmacology. and toxicology. No library serving the

pharmacologic community should he without a subscription.

Qiuiuu’u-/v.

� Plcaxc enter tt�t�. ..tth..crtpltttn E� the lolloo tog:

The journal of Pharmacology and ExperimentalI’herapeutics iit,t’,ttltlvj

-1 mdix idu�tl S I 90/sear 1 loxtitulional S370/�ear ( Add S75/vc�tr fur

suhxcrtpttuns ottt’.tde tic U.S. : to C’�tnada. �t1’.tt �tik1 7� GST.

I � Nc�� Suhx�rtptitttt 1 Rcneo alSuhxcrthe fur: -1 3 vcarx 1 2 yt.-arx 1 1 sear

I)rug \letaholism and I)isposition � ,,iu,tt/tlv

�1 lttijtx Ju�il S9O/� car �1 ltmttttittttnal S I 5O/�� car ( .\dJ 525/s car for suhxcrtpttons

t)LItxtdt.� the �: .s. : to (��ttt�tda. �tlMl add 7( � (ST.

�1 Ncx� Suhxcttptt(In �1 Rcncxx

Suhxcrthc t&tr: 1 3 scar-. �1 2 \carx 1 I scar

I Molecular Pharmacolog� I nuxitltlv I�1 ltkltx idu�tl S I I 5/� t�ar 1 Inxtilutiutial S250/� ear � Add S35/� car for

I suh-.crtpttonx outxtdc the IS.: in Canada. �tlx() add 7� (‘IST. I

�1 Neo Suhx�rtptton 1 Rcnexxal

Suh-..ribc for: �1 3 \earx 1 2 sears 1 I \ear

;:7

!�: �. � � � �.- -.

� � �(

3. �

�.

� .�;:..1.Ii

* � � r .� I

� �i;-4� �

. . I. . ‘l

., . .

:/ . .

,�.,- �:

�Payment Options: � 1 . .

1.Check encloied (payable to

Willi�mis&.Wilkins) . .

1.Bilt me �i A�iierican Express r � � � � � � �

iMasterCard 1VISA Card#

Exp. date Signature or P.O. #

Nanie

Addrcsx

City/State/Zip

�I Plea’.c indicate institution/’�tatus

\tt). II . .itt�l ��lL .uh..criber.. itu..t .idd tate ..ale� t.i�. Siih�� riptirt� ‘tit.,tlc the I S nut heprcpii�l in I S di’tt.it� In J.ip.in. �iiitt.tct lg.iktt-Shiiiii. \tt’iS. Ii,l I 1.1 i �(,iii).c4(Xi R.tc� ‘ �iti�lthritigh ( Ii. tiih�r .i I . I